PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18824519-5 2009 This effect was associated to ERK activation and was blocked by the MAPK/ERK kinase (MEK) inhibitor U0126. U 0126 100-105 mitogen-activated protein kinase 1 Mus musculus 30-33 18824519-5 2009 This effect was associated to ERK activation and was blocked by the MAPK/ERK kinase (MEK) inhibitor U0126. U 0126 100-105 mitogen-activated protein kinase 1 Mus musculus 68-72 18824519-5 2009 This effect was associated to ERK activation and was blocked by the MAPK/ERK kinase (MEK) inhibitor U0126. U 0126 100-105 mitogen-activated protein kinase 1 Mus musculus 73-76 19100675-8 2009 Inhibition of extracellular signal-regulated kinase (ERK) by a MEK/ERK inhibitor, U0126, blocked both phosphorylation and degradation of BIM, resulting in apoptosis. U 0126 82-87 mitogen-activated protein kinase 1 Mus musculus 14-51 19100675-8 2009 Inhibition of extracellular signal-regulated kinase (ERK) by a MEK/ERK inhibitor, U0126, blocked both phosphorylation and degradation of BIM, resulting in apoptosis. U 0126 82-87 mitogen-activated protein kinase 1 Mus musculus 53-56 19100675-8 2009 Inhibition of extracellular signal-regulated kinase (ERK) by a MEK/ERK inhibitor, U0126, blocked both phosphorylation and degradation of BIM, resulting in apoptosis. U 0126 82-87 mitogen-activated protein kinase 1 Mus musculus 67-70 18758753-10 2008 Up-regulated mRNA and protein expression of c-fos and fosB was abolished by SB204741, AG1478, and by U0126, an inhibitor of ERK phosphorylation by MAP kinase/ERK kinase. U 0126 101-106 mitogen-activated protein kinase 1 Mus musculus 124-127 19672126-15 2009 In HCEC, a p38 (SB203580) and a JNK pathway inhibitor (JNK inhibitor I) inhibited migration rates more than U0126-induced ERK, whereas the JNK inhibitor I inactive analogue had no effect. U 0126 108-113 mitogen-activated protein kinase 1 Mus musculus 122-125 18758753-10 2008 Up-regulated mRNA and protein expression of c-fos and fosB was abolished by SB204741, AG1478, and by U0126, an inhibitor of ERK phosphorylation by MAP kinase/ERK kinase. U 0126 101-106 mitogen-activated protein kinase 1 Mus musculus 158-161 18171671-11 2008 Moreover, we have shown that the mitogen-activated protein kinase (ERK1/2) is persistently activated and blockage of ERK activity with the ERK-specific inhibitor U0126 prevents neuronal differentiation. U 0126 162-167 mitogen-activated protein kinase 1 Mus musculus 67-70 18573207-7 2008 We acutely blocked ERK activation in the CeA by infusing the MEK inhibitor U0126 into the right or the left hemisphere and then measured the behavioral effects on inflammation-induced mechanical hypersensitivity in mice. U 0126 75-80 mitogen-activated protein kinase 1 Mus musculus 19-22 18093576-10 2008 Cadmium up-regulates BPDE-activated ERKs and ERK inhibition by U0126 relieves cadmium-mediated inhibition of BPDE-induced apoptosis. U 0126 63-68 mitogen-activated protein kinase 1 Mus musculus 36-40 18171671-11 2008 Moreover, we have shown that the mitogen-activated protein kinase (ERK1/2) is persistently activated and blockage of ERK activity with the ERK-specific inhibitor U0126 prevents neuronal differentiation. U 0126 162-167 mitogen-activated protein kinase 1 Mus musculus 117-120 18334814-8 2008 Surprisingly, we found that selective blocking of extracellular signal-regulated kinase (ERK) signaling by the MAPK/ERK kinase (MEK) inhibitor U0126 affected the expression of only some of the FGF2-regulated genes, suggesting FGF2-induced pathways that are independent of ERK signaling. U 0126 143-148 mitogen-activated protein kinase 1 Mus musculus 50-87 18334814-8 2008 Surprisingly, we found that selective blocking of extracellular signal-regulated kinase (ERK) signaling by the MAPK/ERK kinase (MEK) inhibitor U0126 affected the expression of only some of the FGF2-regulated genes, suggesting FGF2-induced pathways that are independent of ERK signaling. U 0126 143-148 mitogen-activated protein kinase 1 Mus musculus 89-92 18334814-8 2008 Surprisingly, we found that selective blocking of extracellular signal-regulated kinase (ERK) signaling by the MAPK/ERK kinase (MEK) inhibitor U0126 affected the expression of only some of the FGF2-regulated genes, suggesting FGF2-induced pathways that are independent of ERK signaling. U 0126 143-148 mitogen-activated protein kinase 1 Mus musculus 111-115 18334814-8 2008 Surprisingly, we found that selective blocking of extracellular signal-regulated kinase (ERK) signaling by the MAPK/ERK kinase (MEK) inhibitor U0126 affected the expression of only some of the FGF2-regulated genes, suggesting FGF2-induced pathways that are independent of ERK signaling. U 0126 143-148 mitogen-activated protein kinase 1 Mus musculus 116-119 18334814-8 2008 Surprisingly, we found that selective blocking of extracellular signal-regulated kinase (ERK) signaling by the MAPK/ERK kinase (MEK) inhibitor U0126 affected the expression of only some of the FGF2-regulated genes, suggesting FGF2-induced pathways that are independent of ERK signaling. U 0126 143-148 mitogen-activated protein kinase 1 Mus musculus 116-119 18480613-9 2008 Inhibition of ERK phosphorylation by U0126 enhanced podocyte apoptosis induced by PA. U 0126 37-42 mitogen-activated protein kinase 1 Mus musculus 14-17 17910942-5 2007 In addition, it was found that OA inhibited the phosphorylation of ERK1/2, p38 and JNK MAPK, and the treatment of U0126 in LPS-induced raw 264.7 cells showed significant inhibition activity on the NO production and the phosphorylation of IkappaBalpha. U 0126 114-119 mitogen-activated protein kinase 1 Mus musculus 87-91 17980966-7 2007 In contrast, mitogen-activated protein kinase (MAP)/extracellular-signal-regulated kinase (ERK) pathway inhibitor U0126 potentiated insulin-mediated survival. U 0126 114-119 mitogen-activated protein kinase 1 Mus musculus 91-94 18053155-6 2007 We found that P42/P44 MAPK inhibitors, PD98059 and U0126, suppressed the induction of cingulate LTP that was induced by presynaptic stimulation with postsynaptic depolarization (the pairing protocol). U 0126 51-56 mitogen-activated protein kinase 1 Mus musculus 22-26 17971416-7 2007 Preventing activation of the classic MAP kinase cascade with the Erk inhibitor UO126 abolished SDF1-induced proliferation and migration of C2C12 cells but not the inhibitory action of SDF1 on myogenic differentiation. U 0126 79-84 mitogen-activated protein kinase 1 Mus musculus 65-68 18080868-8 2007 Involvement of extracellular signal-regulated kinase (ERK) signaling was assessed using its kinase activity inhibitors PD98059 or U0126. U 0126 130-135 mitogen-activated protein kinase 1 Mus musculus 15-52 18080868-8 2007 Involvement of extracellular signal-regulated kinase (ERK) signaling was assessed using its kinase activity inhibitors PD98059 or U0126. U 0126 130-135 mitogen-activated protein kinase 1 Mus musculus 54-57 17369605-14 2007 In addition, the cytotoxicity of microcystin-LR was attenuated by the inhibitors of MAPK pathways, including U0126, SP600125, and SB203580. U 0126 109-114 mitogen-activated protein kinase 1 Mus musculus 84-88 17500057-5 2007 U0126 and LY249002, specific inhibitors of MAPK/ERK kinase (MEK) and phosphoinositide 3-kinase, respectively, inhibited IGF-1-induced DNA synthesis and migration in both wild-type and LAR(-/-) VSMC. U 0126 0-5 mitogen-activated protein kinase 1 Mus musculus 43-47 17893047-6 2007 Pretreatment with MAPK inhibitors SB203580 and U0126, or addition of the exogenous thiol N-acetylcysteine, abrogated both p38(MAPK) and ERK2 activation as well as downstream effects on gene expression. U 0126 47-52 mitogen-activated protein kinase 1 Mus musculus 136-140 17562163-6 2007 The ERK activation was inhibited by U0126, a specific inhibitor of MEK, but not by LY294002, a specific inhibitor of PI3K, whereas the Akt activation was blocked by LY294002, but not by U0126. U 0126 36-41 mitogen-activated protein kinase 1 Mus musculus 4-7 17662046-8 2007 Furthermore, U0126, a specific inhibitor of the ERK pathway suppressed the persistent pain by formalin. U 0126 13-18 mitogen-activated protein kinase 1 Mus musculus 48-51 17363128-8 2007 Troglitazone-induced cell death was increased by the ERK inhibitor U0126 and prevented by transfection with constitutively active MEK1 and the p38 inhibitor SB203580. U 0126 67-72 mitogen-activated protein kinase 1 Mus musculus 53-56 17074386-5 2007 In N2a cells, the ERK kinase inhibitor U0126 suppressed ERK phosphorylation and abolished the stimulation of CREB phosphorylation produced by H2O2, suggesting that H2O2 enhanced CREB phosphorylation via ERK activation. U 0126 39-44 mitogen-activated protein kinase 1 Mus musculus 18-21 17074386-5 2007 In N2a cells, the ERK kinase inhibitor U0126 suppressed ERK phosphorylation and abolished the stimulation of CREB phosphorylation produced by H2O2, suggesting that H2O2 enhanced CREB phosphorylation via ERK activation. U 0126 39-44 mitogen-activated protein kinase 1 Mus musculus 56-59 17074386-5 2007 In N2a cells, the ERK kinase inhibitor U0126 suppressed ERK phosphorylation and abolished the stimulation of CREB phosphorylation produced by H2O2, suggesting that H2O2 enhanced CREB phosphorylation via ERK activation. U 0126 39-44 mitogen-activated protein kinase 1 Mus musculus 56-59 17449940-7 2007 Interestingly, the ERK pathway inhibitor, UO126, reversed the apoptotic effects of S1P on B16 melanoma cells. U 0126 42-47 mitogen-activated protein kinase 1 Mus musculus 19-22 17241117-6 2007 By contrast, glutamate induced a strong phosphorylation of histone H3 that was inhibited by selective inhibitors of the extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase (p38 MAPK) pathways, U0126 and SB203580, respectively. U 0126 226-231 mitogen-activated protein kinase 1 Mus musculus 159-162 17353023-11 2007 Behavioral experiments showed that U0126 (0.5-2.5nmol), a MAP kinase-ERK inhibitor, dose-dependently attenuated the behavioral response to i.t. U 0126 35-40 mitogen-activated protein kinase 1 Mus musculus 69-72 17267741-10 2007 Both plasmin-induced ERK activation and EMT were significantly blocked in vitro by the protease-activated receptor-1 (PAR-1) silencing RNA; by pepducin, a specific anti-PAR-1 signaling peptide; and by the ERK kinase inhibitor UO126. U 0126 226-231 mitogen-activated protein kinase 1 Mus musculus 21-24 17197172-5 2007 Hormone-dependent ERK and p38 activation was abolished by MAPK specific inhibitors U0126 and SB203580. U 0126 83-88 mitogen-activated protein kinase 1 Mus musculus 18-21 17197172-5 2007 Hormone-dependent ERK and p38 activation was abolished by MAPK specific inhibitors U0126 and SB203580. U 0126 83-88 mitogen-activated protein kinase 1 Mus musculus 58-62 16941494-5 2006 We observed that U0126, an inhibitor of ERK activation, decreased basal survival of these cells. U 0126 17-22 mitogen-activated protein kinase 1 Mus musculus 40-43 16824602-7 2007 A specific ERK inhibitor, U0126, as well as PI3K inhibitors, differentially regulated IL-10 and IL-12 p70 productions. U 0126 26-31 mitogen-activated protein kinase 1 Mus musculus 11-14 17404063-8 2007 Pretreatment with U0126 and SB203580, pharmacological inhibitors of ERK and p38 MAPK, respectively, showed that SB203580, but not U0126, attenuated TPA-induced CREB DNA binding in mouse skin. U 0126 18-23 mitogen-activated protein kinase 1 Mus musculus 68-71 17202371-12 2007 Finally, the administration of U0126, an inhibitor of ERK activation, to infected mice resulted in decreased lesion progression with reduced numbers of parasites in them. U 0126 31-36 mitogen-activated protein kinase 1 Mus musculus 54-57 17241271-9 2007 Remarkably, U0126, an inhibitor of ERK activation, at doses which reduced the hyperactive pERK levels in NF1(+/-) mice to the levels observed in control mice, caused a reduction in the deficits in early-phase LTP and completely rescued the long-term LTP deficits. U 0126 12-17 mitogen-activated protein kinase 1 Mus musculus 35-38 17564756-9 2007 Moreover, in FL-RAGE cells, decreased protein levels of the cdk inhibitor p16 were observed, and the p42/44 MAPK inhibitor UO126 prevented AGE and S100B stimulated cyclin D(1) expression and hindered cells to enter the S-phase. U 0126 123-128 mitogen-activated protein kinase 1 Mus musculus 108-112 17026715-9 2006 Finally, caspase-3 activation was observed in the presence of UO126, suggesting that the ERK pathway also contributes to the survival of differentiating ES cells. U 0126 62-67 mitogen-activated protein kinase 1 Mus musculus 89-92 16847309-3 2006 Indeed, inhibition of ERK1/ERK2 phosphorylation by DHA, U0126 [chemical MAPK extracellularly signal-regulated kinase kinase (MEK) inhibitor], and MEK(SA) (cells expressing dominant negative constructs of MEK) resulted in the accumulation of p27(Kip1). U 0126 56-61 mitogen-activated protein kinase 1 Mus musculus 27-31 16880206-3 2006 Here, we report that Fyn, NFAT, and ERK signaling influence ICOS expression as various chemical inhibitors, such as PP2 that targets Src kinases, U0126 that targets MEK1/2, and cyclosporin A or FK506 that targets calcineurin and thereby affects NFAT, attenuate T cell receptor-mediated ICOS induction. U 0126 146-151 mitogen-activated protein kinase 1 Mus musculus 36-39 16864584-3 2006 A functional MEK-ERK pathway is an important requirement for CB1-mediated Krox-24 induction as blockade of MEK signaling by UO126 reduces both basal and CB1-mediated activation of Krox-24. U 0126 124-129 mitogen-activated protein kinase 1 Mus musculus 17-20 16473382-5 2006 Although pretreatment with ERK inhibitors (PD98059 or U0126) abolished ERK phosphorylation in response to NDGA, neither inhibitor had any effect on NDGA-induced apoptosis. U 0126 54-59 mitogen-activated protein kinase 1 Mus musculus 27-30 16893987-7 2006 When ERK activation was suppressed by an inhibitor (U0126), production of p40 rose from an undetectable to a substantial level and GA-12 activation decreased. U 0126 52-57 mitogen-activated protein kinase 1 Mus musculus 5-8 16901926-9 2006 Furthermore, TGFalpha increased phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2) and cAMP-response element-binding protein (CREB), processes inhibited by the mitogen-activated protein kinase/ERK inhibitor U0126 and by expression of non-phosphorylatable CREB-M1 respectively. U 0126 227-232 mitogen-activated protein kinase 1 Mus musculus 95-98 17004925-6 2006 In addition, U0126, a specific inhibitor of the MAPK kinase-ERK1/2 pathway, abrogated the induction of LTD in cerebellar slices, whereas SB203580 and SP600125, specific inhibitors of p38 MAPK and JNK, respectively, had no effect. U 0126 13-18 mitogen-activated protein kinase 1 Mus musculus 48-52 17004925-6 2006 In addition, U0126, a specific inhibitor of the MAPK kinase-ERK1/2 pathway, abrogated the induction of LTD in cerebellar slices, whereas SB203580 and SP600125, specific inhibitors of p38 MAPK and JNK, respectively, had no effect. U 0126 13-18 mitogen-activated protein kinase 1 Mus musculus 187-191 16955795-9 2006 The inhibiting effect, moreover, could be blocked by the specific inhibitor of MAPK pathway, U0126. U 0126 93-98 mitogen-activated protein kinase 1 Mus musculus 79-83 16473382-5 2006 Although pretreatment with ERK inhibitors (PD98059 or U0126) abolished ERK phosphorylation in response to NDGA, neither inhibitor had any effect on NDGA-induced apoptosis. U 0126 54-59 mitogen-activated protein kinase 1 Mus musculus 71-74 16753025-14 2006 Pretreating MC3T3-E1 cells with the mitogen-activated protein kinase (MAPK)/ERK kinase 1/2 (MEK1/2) inhibitor, U0126, or H-89, a PKA inhibitor, significantly inhibited the induction of fgf-2, showing that mechanical induction of fgf-2 is dependent on ERK and PKA signaling pathways. U 0126 111-116 mitogen-activated protein kinase 1 Mus musculus 251-254 16809321-7 2006 The treatment of cells with U0126, a specific inhibitor of ERK activation, resulted in a substantial delay in the release of virus from infected cells that was more pronounced with a virus deleted for Us2 than with parental and repaired strains, suggesting that both ERK and Us2 activities are required for efficient virus replication. U 0126 28-33 mitogen-activated protein kinase 1 Mus musculus 59-62 16809321-7 2006 The treatment of cells with U0126, a specific inhibitor of ERK activation, resulted in a substantial delay in the release of virus from infected cells that was more pronounced with a virus deleted for Us2 than with parental and repaired strains, suggesting that both ERK and Us2 activities are required for efficient virus replication. U 0126 28-33 mitogen-activated protein kinase 1 Mus musculus 267-270 16882022-6 2006 Moreover, we found that inhibition of the MAPK/ERK signalling pathway by intrabasolateral amygdala infusion of the MEK inhibitor, U0126, completely blocks acquisition of extinction. U 0126 130-135 mitogen-activated protein kinase 1 Mus musculus 42-46 16882022-6 2006 Moreover, we found that inhibition of the MAPK/ERK signalling pathway by intrabasolateral amygdala infusion of the MEK inhibitor, U0126, completely blocks acquisition of extinction. U 0126 130-135 mitogen-activated protein kinase 1 Mus musculus 47-50 16639077-6 2006 The increase in inflammatory gene expression coincided with the phosphorylation of the mitogen-activated protein kinase (MAPK) pathway members extracellular signal-regulated kinase (ERK) 1/2, stress-activated protein kinase/c-Jun NH2-terminal kinase, and p38 MAPK and was ameliorated by U0126, an inhibitor of ERK1/2. U 0126 287-292 mitogen-activated protein kinase 1 Mus musculus 121-125 16527246-8 2006 U0126, an inhibitor of the extracellular signal-regulated kinase (ERK), significantly down-regulated lipopolysaccharide (LPS)-induced iNOS expression and promoter activity. U 0126 0-5 mitogen-activated protein kinase 1 Mus musculus 27-64 16527246-8 2006 U0126, an inhibitor of the extracellular signal-regulated kinase (ERK), significantly down-regulated lipopolysaccharide (LPS)-induced iNOS expression and promoter activity. U 0126 0-5 mitogen-activated protein kinase 1 Mus musculus 66-69 16166197-7 2006 IGF-I increased phosphorylation of ERK1/2, an event inhibited by the MAPK/ERK inhibitors, PD98059 and U0126. U 0126 102-107 mitogen-activated protein kinase 1 Mus musculus 69-73 16476053-9 2006 Inhibition of ERK activity, by the inhibitor U0126, reduced LPS-induced iNOS expression in our cell lines. U 0126 45-50 mitogen-activated protein kinase 1 Mus musculus 14-17 16420578-5 2006 Preventing ERK2 activation by U0126 prolonged occlusion times in TG (41 +/- 10 min) and WT (51 +/- 17) arterioles more than in TG (46 +/- 5 min) and WT (56 +/- 6 min) venules, uncovering a role for ERK2 in shear controlled thrombosis. U 0126 30-35 mitogen-activated protein kinase 1 Mus musculus 11-15 16420578-5 2006 Preventing ERK2 activation by U0126 prolonged occlusion times in TG (41 +/- 10 min) and WT (51 +/- 17) arterioles more than in TG (46 +/- 5 min) and WT (56 +/- 6 min) venules, uncovering a role for ERK2 in shear controlled thrombosis. U 0126 30-35 mitogen-activated protein kinase 1 Mus musculus 198-202 16187294-6 2006 Furthermore, inhibition of mitogen-activated protein kinase (Erk-MAPK) in the mouse microglial cell line BV2 by U0126 indicated that the MAP kinase signaling pathway may be involved in the regulation of NO and integrin alpha5 production by GDNF. U 0126 112-117 mitogen-activated protein kinase 1 Mus musculus 61-64 16187294-6 2006 Furthermore, inhibition of mitogen-activated protein kinase (Erk-MAPK) in the mouse microglial cell line BV2 by U0126 indicated that the MAP kinase signaling pathway may be involved in the regulation of NO and integrin alpha5 production by GDNF. U 0126 112-117 mitogen-activated protein kinase 1 Mus musculus 65-69 16187294-8 2006 Furthermore, inhibition of Erk-MAPK in the mouse microglial cell line BV2 by U0126 indicated that the MAP kinase signaling pathway may be involved in the regulation of NO and integrin alpha5 production by GDNF. U 0126 77-82 mitogen-activated protein kinase 1 Mus musculus 27-30 16187294-8 2006 Furthermore, inhibition of Erk-MAPK in the mouse microglial cell line BV2 by U0126 indicated that the MAP kinase signaling pathway may be involved in the regulation of NO and integrin alpha5 production by GDNF. U 0126 77-82 mitogen-activated protein kinase 1 Mus musculus 31-35 16166197-7 2006 IGF-I increased phosphorylation of ERK1/2, an event inhibited by the MAPK/ERK inhibitors, PD98059 and U0126. U 0126 102-107 mitogen-activated protein kinase 1 Mus musculus 35-38 15626475-8 2005 Thus ERK MAPKs regulate expression of TMEV-induced p19 differently than p40 and IFN-beta suggesting the benefits of U0126 in treatment of DD. U 0126 116-121 mitogen-activated protein kinase 1 Mus musculus 5-8 15908120-5 2005 U0126, an inhibitor of the MEK kinases, blocked the CART-stimulated activation of ERKs. U 0126 0-5 mitogen-activated protein kinase 1 Mus musculus 82-86 15963474-7 2005 MAPK inhibitors (U0126 for MEK1/2, SB203580 for p38 kinase and SP600125 for JNK) specifically blocked LPS-induced COX-2 expression. U 0126 17-22 mitogen-activated protein kinase 1 Mus musculus 0-4 15894174-5 2005 Furthermore, PD98059 or U0126 hardly blocked the heat-induced activation of ERK. U 0126 24-29 mitogen-activated protein kinase 1 Mus musculus 76-79 15833106-14 2005 Using a murine asthma model of late phase eosinophilia, we demonstrated that the ERK inhibitor U0126 and the JNK inhibitor SP600125 inhibited lung inflammation in vivo. U 0126 95-100 mitogen-activated protein kinase 1 Mus musculus 81-84 15833106-17 2005 In contrast, we found that the p38 inhibitor SB203580 antagonizes the action of the ERK inhibitor U0126 in vitro and in vivo. U 0126 98-103 mitogen-activated protein kinase 1 Mus musculus 84-87 15653932-6 2005 Western blot analysis showed that TNF-alpha activated the extracellular signal-regulated kinase (ERK), and inhibitors of the ERK-specific mitogen-activated protein kinase pathway (PD98059 or U0126) blocked TNF-alpha induction of TGF-beta(1) mRNA and protein. U 0126 191-196 mitogen-activated protein kinase 1 Mus musculus 58-95 15653932-6 2005 Western blot analysis showed that TNF-alpha activated the extracellular signal-regulated kinase (ERK), and inhibitors of the ERK-specific mitogen-activated protein kinase pathway (PD98059 or U0126) blocked TNF-alpha induction of TGF-beta(1) mRNA and protein. U 0126 191-196 mitogen-activated protein kinase 1 Mus musculus 97-100 15653932-6 2005 Western blot analysis showed that TNF-alpha activated the extracellular signal-regulated kinase (ERK), and inhibitors of the ERK-specific mitogen-activated protein kinase pathway (PD98059 or U0126) blocked TNF-alpha induction of TGF-beta(1) mRNA and protein. U 0126 191-196 mitogen-activated protein kinase 1 Mus musculus 125-128 15728252-5 2005 Inhibition of MEK/ERK signaling in wild-type MK cells with a pharmacological inhibitor, U0126, showed that ERK activation was necessary for high levels of endogenous MMP-9 gene expression and activity of a transfected MMP-9 promoter. U 0126 88-93 mitogen-activated protein kinase 1 Mus musculus 18-21 15728252-5 2005 Inhibition of MEK/ERK signaling in wild-type MK cells with a pharmacological inhibitor, U0126, showed that ERK activation was necessary for high levels of endogenous MMP-9 gene expression and activity of a transfected MMP-9 promoter. U 0126 88-93 mitogen-activated protein kinase 1 Mus musculus 107-110 15572374-3 2005 Cotreatment of hepa1c1c7 cells with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and Erk kinase inhibitor PD98059, U0126, or SL327 led to enhanced nuclear accumulation of Ah receptor but with a reduced capacity to complement TCDD induction of Cyp1a1. U 0126 113-118 mitogen-activated protein kinase 1 Mus musculus 83-86 16164983-4 2005 Inhibition of the MEK/ERK pathway by pretreatment with the MEK inhibitor U 0126 dramatically attenuated G-CSF-induced granulocytic differentiation and IL-6-induced monocytic differentiation. U 0126 73-79 mitogen-activated protein kinase 1 Mus musculus 22-25 16103085-6 2005 Inhibiting both MAPK kinase (MEK)/ERK and PKA pathways by a combination of U0126 (10 micromol/L) and H-89 (5 micromol/L) reduced most of BAD phosphorylation at Ser112 and induced apoptosis to a level comparable with that induced by FLT3 inhibitor AG1296 (5 micromol/L) in BaF3/FLT3/ITD cells. U 0126 75-80 mitogen-activated protein kinase 1 Mus musculus 34-37 15899786-7 2005 In addition, inhibition of ERK activation by exposing MEFs to the MEK1/2-specific inhibitors PD98059 and U0126 protected both KSR+/+ and KSR-/- MEFs cells from CDDP-induced apoptosis. U 0126 105-110 mitogen-activated protein kinase 1 Mus musculus 27-30 15843032-6 2005 Treatment of myoblasts with LIF induced phosphorylation of ERK, and the LIF-induced inhibitory effect on myogenesis was blocked by pretreatment with U0126, a specific MEK inhibitor, and transient transfection with dominant negative (DN)-MEK1. U 0126 149-154 mitogen-activated protein kinase 1 Mus musculus 59-62 15749808-5 2005 Interestingly, a specific inhibitor for MEK, U0126, efficiently blocked the induction of TH promoter activity by activin A and bFGF, indicating that activin A collaborated with bFGF signaling to induce the TH gene through selective activation of ERK-type MAP kinase in mouse striatal and HT22 cells. U 0126 45-50 mitogen-activated protein kinase 1 Mus musculus 246-249 15572029-6 2005 LIF could activate MEK1/2 and STAT3, but LIF-induced differentiation was blocked only by the MEK1/2-specific inhibitor U0126, indicating that the MEK/ERK pathway is necessary for LIF action in MPC cells. U 0126 119-124 mitogen-activated protein kinase 1 Mus musculus 150-153 15664007-11 2005 U0126, a specific inhibitor of the ERK pathway, completely blocked both TGF(beta)- and PGE2-induced cell proliferation whereas SB203580 and SP600125, which are selective inhibitors of, respectively, p38 and JNK pathways, had no effect. U 0126 0-5 mitogen-activated protein kinase 1 Mus musculus 35-38 15669185-0 2004 U0126 prevents ERK pathway phosphorylation and interleukin-1beta mRNA production after cerebral ischemia. U 0126 0-5 mitogen-activated protein kinase 1 Mus musculus 15-18 15669185-12 2004 The protective effect of U0126 against ischemic injury is probably resulted from the reduction of IL-1beta mRNA via the inhibition of ERK pathway. U 0126 25-30 mitogen-activated protein kinase 1 Mus musculus 134-137 15504369-9 2004 TGF-beta production was completely inhibited by U0126, a specific inhibitor for ERK. U 0126 48-53 mitogen-activated protein kinase 1 Mus musculus 80-83 15322121-9 2004 Phosphorylation of Erk and tau was reduced by preincubation with the Erk pathway inhibitor U0126. U 0126 91-96 mitogen-activated protein kinase 1 Mus musculus 19-22 15660418-9 2004 Inhibition of the ERK pathway by PD98059 and U0126 inhibited proliferation but did not inhibit migration. U 0126 45-50 mitogen-activated protein kinase 1 Mus musculus 18-21 15331624-4 2004 Pharmacological suppression of p38 or ERK1/2 MAPK with specific inhibitors (SB203580, SB202190, U0126, or PD98059) significantly attenuated LPS-induced TNF production but failed to inhibit LPS-induced HMGB1 release. U 0126 96-101 mitogen-activated protein kinase 1 Mus musculus 45-49 15331595-5 2004 Inhibition of ERK activation by the MEK inhibitor, U0126, stimulated VDR activity in MC3T3-E1 cells, but inhibited the activity in MG-63 cells as well as in HeLa cells. U 0126 51-56 mitogen-activated protein kinase 1 Mus musculus 14-17 15322121-9 2004 Phosphorylation of Erk and tau was reduced by preincubation with the Erk pathway inhibitor U0126. U 0126 91-96 mitogen-activated protein kinase 1 Mus musculus 69-72 15174091-5 2004 Conversely, treatment with U0126, a potent inhibitor of MEK-mediated ERK activation, prevented FAK phosphorylation at Ser-910 induced by PDGF but did not interfere with PDGF-induced FAK phosphorylation at Tyr-397. U 0126 27-32 mitogen-activated protein kinase 1 Mus musculus 69-72 15548370-9 2004 Treatment with an MEK inhibitor, U0126, inhibited increased Erk phosphorylation and kinase activity, and blocked TGF-beta1-induced EMT in both cell lines. U 0126 33-38 mitogen-activated protein kinase 1 Mus musculus 60-63 15380445-3 2004 Ox-LDL-induced proliferation of mouse peritoneal macrophages assessed by [3H]thymidine incorporation and cell counting assays was significantly inhibited by MEK1/2 inhibitors, PD98059 or U0126, and p38 MAPK inhibitors, SB203580 or SB202190, respectively. U 0126 187-192 mitogen-activated protein kinase 1 Mus musculus 202-206 15063796-3 2004 Use of a pharmacological inhibitor (U0126) demonstrated that extracellular signal regulated kinase (ERK) plays a major role in TPA-induced MMP-13 gene expression. U 0126 36-41 mitogen-activated protein kinase 1 Mus musculus 61-98 15153527-5 2004 Intraperitoneal administration of U0126, a specific MAPK/ERK kinase inhibitor, significantly (p < 0.05) inhibited OVA-induced increases in total cell counts, eosinophil counts, and IL-4, IL-5, IL-13, and eotaxin levels recovered in bronchoalveolar lavage fluid in a dose-dependent manner. U 0126 34-39 mitogen-activated protein kinase 1 Mus musculus 52-56 15153527-5 2004 Intraperitoneal administration of U0126, a specific MAPK/ERK kinase inhibitor, significantly (p < 0.05) inhibited OVA-induced increases in total cell counts, eosinophil counts, and IL-4, IL-5, IL-13, and eotaxin levels recovered in bronchoalveolar lavage fluid in a dose-dependent manner. U 0126 34-39 mitogen-activated protein kinase 1 Mus musculus 57-60 15063796-3 2004 Use of a pharmacological inhibitor (U0126) demonstrated that extracellular signal regulated kinase (ERK) plays a major role in TPA-induced MMP-13 gene expression. U 0126 36-41 mitogen-activated protein kinase 1 Mus musculus 100-103 14585838-7 2004 The increased expression of apoE was almost completely abolished by incubating neurons with U0126, an inhibitor of extracellular signal-regulated kinase (Erk), suggesting that the Erk pathway controls astroglial regulation of apoE expression in neuronal cells. U 0126 92-97 mitogen-activated protein kinase 1 Mus musculus 115-152 14605001-5 2004 Both PACAP-38 and VIP also rapidly induced ERK1/2 phosphorylation and their stimulatory effect on NNT-1/BSF-3 mRNA expression was reduced by the MAPK kinase/ERK kinase (MEK) inhibitor U0126 (10 microm). U 0126 184-189 mitogen-activated protein kinase 1 Mus musculus 145-149 14684387-5 2004 Interestingly, a persistent reduction in I kappa B alpha levels is also observed when the MEK1/2 inhibitor U0126 is coadministered with LPS, suggesting that components of the MEK/ERK pathway are involved in regulating I kappa B alpha protein expression and/or turnover. U 0126 107-112 mitogen-activated protein kinase 1 Mus musculus 179-182 14684387-6 2004 The observation that U0126 and BzATP exhibit overlapping actions with respect to LPS-induced changes in I kappa B alpha levels is supported by the finding that Ras activation, which is upstream of MEK/ERK activation, is reduced upon macrophage cotreatment with BzATP and LPS compared with the effects of BzATP treatment alone. U 0126 21-26 mitogen-activated protein kinase 1 Mus musculus 201-204 14585838-7 2004 The increased expression of apoE was almost completely abolished by incubating neurons with U0126, an inhibitor of extracellular signal-regulated kinase (Erk), suggesting that the Erk pathway controls astroglial regulation of apoE expression in neuronal cells. U 0126 92-97 mitogen-activated protein kinase 1 Mus musculus 154-157 14585838-7 2004 The increased expression of apoE was almost completely abolished by incubating neurons with U0126, an inhibitor of extracellular signal-regulated kinase (Erk), suggesting that the Erk pathway controls astroglial regulation of apoE expression in neuronal cells. U 0126 92-97 mitogen-activated protein kinase 1 Mus musculus 180-183 14517212-5 2003 The MEK inhibitors PD 98059 and U0126 blocked ERK phosphorylation, as did the adenylate cyclase activator forskolin. U 0126 32-37 mitogen-activated protein kinase 1 Mus musculus 46-49 12941468-7 2003 The upstream inhibitor of ERK phosphorylation, U0126 (100-400 microg/kg, i.v., 10 min pre-capsaicin), dose-dependently inhibited referred hyperalgesia 3-6 h after capsaicin. U 0126 47-52 mitogen-activated protein kinase 1 Mus musculus 26-29 14672561-8 2003 When the concentration of U0126 was increased to 15 mM, the phosphorylation of both MAPK and p90rsk were inhibited, while symmetric division was decreased. U 0126 26-31 mitogen-activated protein kinase 1 Mus musculus 84-88 14570609-4 2003 An ERK pathway inhibitor, 1,4-diamino-2,3-dicyano-1,4-bis[2-amino-phenylthio] butadiene (U0126), was administered intravenously 20 minutes before MCAO, and the neurological deficit levels and the infarct volumes were measured 24 hours after MCAO. U 0126 26-87 mitogen-activated protein kinase 1 Mus musculus 3-6 14570609-4 2003 An ERK pathway inhibitor, 1,4-diamino-2,3-dicyano-1,4-bis[2-amino-phenylthio] butadiene (U0126), was administered intravenously 20 minutes before MCAO, and the neurological deficit levels and the infarct volumes were measured 24 hours after MCAO. U 0126 89-94 mitogen-activated protein kinase 1 Mus musculus 3-6 12904462-7 2003 Visual stimulation triggered a prolonged episode of CRE-mediated gene expression in the visual cortex that was suppressed by infusion with the ERK inhibitor U0126. U 0126 157-162 mitogen-activated protein kinase 1 Mus musculus 143-146 14584892-14 2003 Inhibition of ERK phosphorylation with the specific inhibitors, PD-98059 and U-0126, decreased the [Ca2+]e induction of both COX-2 mRNA and luciferase activity by 70-80%. U 0126 77-83 mitogen-activated protein kinase 1 Mus musculus 14-17 12929133-6 2003 The inhibitors of NF-kappaB (pyrrolidine dithiocarbamate, PDTC) and ERK (1,4-diamino-2,3-dicyano-1,4 bis[2-aminophenylthio]butadiene; U0126) markedly decreased synergistic NO production in BV2 cells treated with IFN-gamma and PMA in combination. U 0126 73-132 mitogen-activated protein kinase 1 Mus musculus 68-71 12801933-7 2003 Treatment of LY-ar cells with the MEK inhibitors PD 98059, U0126, and PD 184352 led to a loss of phosphorylated ERK1 and ERK2, a reversal of nuclear p50 homodimer DNA binding, and a decrease in Bcl-2 protein expression. U 0126 59-64 mitogen-activated protein kinase 1 Mus musculus 121-125 11923207-4 2002 By using the MEK inhibitor U0126, we have demonstrated that activation of p90Rsk2 during meiotic progression requires activation of the MAPK pathway. U 0126 27-32 mitogen-activated protein kinase 1 Mus musculus 136-140 12676927-11 2003 Inhibition of the ERK and protein kinase C signaling pathways with the MEK-1 inhibitor, U0126, and protein kinase C inhibitor, GF 1092030x, respectively, and chelating intracellular free calcium with 1,2-bis(2-aminophenoyl)ethane-N,N,N",N"-tetraacetic acid-AM, which also reduced ERK1/2 activation, significantly reduced H2O2-induced AA release in MC+/+ expressing either group IIa or V PLA2s. U 0126 88-93 mitogen-activated protein kinase 1 Mus musculus 18-21 12538600-2 2003 We find that ERK activity is essential for serum-induced osteoblast proliferation in vitro because inhibition of MAPK/ERK kinase activity by U0126 completely abolished both serum-induced activation of ERK and proliferation of mouse (MBA-15.4) and human (MG-63) osteoblast cell lines. U 0126 141-146 mitogen-activated protein kinase 1 Mus musculus 13-16 12538600-2 2003 We find that ERK activity is essential for serum-induced osteoblast proliferation in vitro because inhibition of MAPK/ERK kinase activity by U0126 completely abolished both serum-induced activation of ERK and proliferation of mouse (MBA-15.4) and human (MG-63) osteoblast cell lines. U 0126 141-146 mitogen-activated protein kinase 1 Mus musculus 118-121 12538600-2 2003 We find that ERK activity is essential for serum-induced osteoblast proliferation in vitro because inhibition of MAPK/ERK kinase activity by U0126 completely abolished both serum-induced activation of ERK and proliferation of mouse (MBA-15.4) and human (MG-63) osteoblast cell lines. U 0126 141-146 mitogen-activated protein kinase 1 Mus musculus 118-121 12270548-7 2002 Tyrosine phosphorylation of ERK was detected after stimulation with IL-3 or MSP, whereas treatment with U0126 specifically inhibited IL-3- or MSP-induced ERK phosphorylation but not tyrosine phosphorylation of betac. U 0126 104-109 mitogen-activated protein kinase 1 Mus musculus 154-157 12110689-12 2002 Furthermore, a specific ERK1/2 phosphorylation inhibitor, U0126, completely blocked both FGF-2-stimulated Runx2 phosphorylation and osteocalcin promoter activity, indicating that this regulation requires the MAPK pathway. U 0126 58-63 mitogen-activated protein kinase 1 Mus musculus 208-212 11918738-9 2002 ERK was activated during apoptosis and blocking ERK activation with U0126 or PD98059 partially rescued MC from apoptosis. U 0126 68-73 mitogen-activated protein kinase 1 Mus musculus 0-3 11918738-9 2002 ERK was activated during apoptosis and blocking ERK activation with U0126 or PD98059 partially rescued MC from apoptosis. U 0126 68-73 mitogen-activated protein kinase 1 Mus musculus 48-51 12692126-6 2003 Treatment with the ERK inhibitors U0126 and PD98059 prevented FAK phosphorylation at Ser-910 in response to all of the stimuli tested. U 0126 34-39 mitogen-activated protein kinase 1 Mus musculus 19-22 12711247-11 2003 On the contrary, U0126, which inhibits an upstream kinase of Erk (MEK), did not affect PGF(2alpha)-induced enhancement of Pi transport. U 0126 17-22 mitogen-activated protein kinase 1 Mus musculus 61-64 12490006-6 2002 Treatment with U0126, which inhibits MEK, the kinase upstream of ERK, effectively prevented the activation of ERK. U 0126 15-20 mitogen-activated protein kinase 1 Mus musculus 65-68 12490006-6 2002 Treatment with U0126, which inhibits MEK, the kinase upstream of ERK, effectively prevented the activation of ERK. U 0126 15-20 mitogen-activated protein kinase 1 Mus musculus 110-113 12438155-5 2002 The MAP kinase kinase inhibitor U0126 inhibits both baseline proliferation and stimulated process outgrowth, consistent with a model in which sustained low-level ERK activation drives proliferation, and more intense activation drives neuronal differentiation. U 0126 32-37 mitogen-activated protein kinase 1 Mus musculus 162-165 12412688-7 2002 In isolated perfused mouse lungs, the MAPK/ERK kinase inhibitor U0126 prevented ventilation-induced activation of ERK-1/2 and Elk-1, but had no effect on ventilation-induced cytokine release. U 0126 64-69 mitogen-activated protein kinase 1 Mus musculus 38-42 12412688-7 2002 In isolated perfused mouse lungs, the MAPK/ERK kinase inhibitor U0126 prevented ventilation-induced activation of ERK-1/2 and Elk-1, but had no effect on ventilation-induced cytokine release. U 0126 64-69 mitogen-activated protein kinase 1 Mus musculus 43-46 12423237-3 2002 However, complete inhibition of phospho-ERK by U0126, an inhibitor of mitogen-activated protein kinase kinase (MEK), did not completely inhibit PMA-stimulated cPLA2 and AA release. U 0126 47-52 mitogen-activated protein kinase 1 Mus musculus 40-43 12063170-7 2002 The MEK-inhibitor, U0126, that specifically inhibits the activation of ERK also blocked the phosphorylation of p66shc and Raf-1, suggesting that these processes were MEK-dependent, quite different from that which was observed in A549 cells. U 0126 19-24 mitogen-activated protein kinase 1 Mus musculus 71-74 12070303-6 2002 Inhibition of ERK-1/2 with UO126 reduced CVB3 titers in Jurkat cells, but not in JCaM cells. U 0126 27-32 mitogen-activated protein kinase 1 Mus musculus 14-21 12019309-9 2002 These effects were blocked by U0126, a mitogen-activated protein kinase/Erk kinase 1/2 inhibitor, suggesting an association between Bad phosphorylation and MAPK activation. U 0126 30-35 mitogen-activated protein kinase 1 Mus musculus 156-160 12019309-10 2002 Notably, U0126 and a Rsk1 inhibitor (Ro318220) abolished the neuroprotective activity of TGF-beta1 in staurosporine-induced apoptosis, indicating that activation of MAPK is necessary for the antiapoptotic effect of TGF-beta1 in cultured hippocampal cells. U 0126 9-14 mitogen-activated protein kinase 1 Mus musculus 165-169 11900461-8 2002 When in vitro-grown oocytes were treated with UO126, a specific MEK inhibitor that prevents activation of mitogen-activated protein kinases (ERK-1 and ERK-2), for 1 h before, during, and following OA treatment, only 22% of oocytes underwent germinal vesicle breakdown after 24 h from the OA treatment. U 0126 46-51 mitogen-activated protein kinase 1 Mus musculus 151-156 11784715-4 2002 In addition, HGF induced association of paxillin and activated ERK, correlating with a gel retardation of paxillin that was prevented with the ERK inhibitor U0126. U 0126 157-162 mitogen-activated protein kinase 1 Mus musculus 63-66 11784715-4 2002 In addition, HGF induced association of paxillin and activated ERK, correlating with a gel retardation of paxillin that was prevented with the ERK inhibitor U0126. U 0126 157-162 mitogen-activated protein kinase 1 Mus musculus 143-146 11756441-2 2002 Whereas small molecule inhibitors PD098095 and U0126 have been used to study MAPK/ERK kinase (MEK), their target selectivity has been questioned recently. U 0126 47-52 mitogen-activated protein kinase 1 Mus musculus 77-81 11923207-10 2002 We show that inhibition of the MAPK pathway by preincubation of spermatocytes with U0126 suppresses Nek2 activation, and that incubation of spermatocyte cell extracts with activated p90Rsk2 causes stimulation of Nek2 kinase activity. U 0126 83-88 mitogen-activated protein kinase 1 Mus musculus 31-35 11771655-10 2002 U0126, a specific inhibitor of MAPK/extracellular signal-regulated kinase (MEK), blocked AA- or BMP-7/AA-dependent gene expression in a time- and dose-dependent manner that was closely correlated with inhibition of extracellular signal-regulated kinase (ERK) phosphorylation. U 0126 0-5 mitogen-activated protein kinase 1 Mus musculus 36-73 11771655-10 2002 U0126, a specific inhibitor of MAPK/extracellular signal-regulated kinase (MEK), blocked AA- or BMP-7/AA-dependent gene expression in a time- and dose-dependent manner that was closely correlated with inhibition of extracellular signal-regulated kinase (ERK) phosphorylation. U 0126 0-5 mitogen-activated protein kinase 1 Mus musculus 215-252 11771655-10 2002 U0126, a specific inhibitor of MAPK/extracellular signal-regulated kinase (MEK), blocked AA- or BMP-7/AA-dependent gene expression in a time- and dose-dependent manner that was closely correlated with inhibition of extracellular signal-regulated kinase (ERK) phosphorylation. U 0126 0-5 mitogen-activated protein kinase 1 Mus musculus 254-257 11571295-6 2001 However, using an inhibitor of ERK activation, U0126, we show that Alb-AGE stimulates VEGF expression through an ERK-dependent pathway. U 0126 47-52 mitogen-activated protein kinase 1 Mus musculus 113-116 11739023-5 2001 Pre-treatment of alpha T3-1 cells with the specific MAPK kinase (MEK) inhibitor, U0126, blocked PACAP and EGF-induced activation of ERK. U 0126 81-86 mitogen-activated protein kinase 1 Mus musculus 132-135 11592732-4 2001 PMA acts upstream of MEK and via activation of protein kinase C (PKC), as GF109203X, a potent PKC inhibitor, and U0126, a MEK inhibitor, abolished its actions on ERK1/ERK2 phosphorylation. U 0126 113-118 mitogen-activated protein kinase 1 Mus musculus 167-171 11701758-9 2001 Cytotoxicity was also attenuated by MEK inhibition with PD98059 or U0126 at concentrations that were sufficient to prevent ERK activation. U 0126 67-72 mitogen-activated protein kinase 1 Mus musculus 123-126 11504919-7 2001 administration of U0126 (100-200 mg/kg), a specific inhibitor of MEK (MAPK/ERK kinase), protects the hippocampus against forebrain ischemia. U 0126 18-23 mitogen-activated protein kinase 1 Mus musculus 75-78 11399647-7 2001 Inhibition of ERK activation with U0126 completely blocked the HGF-dependent reversal of ATP-depleted cell adhesion. U 0126 34-39 mitogen-activated protein kinase 1 Mus musculus 14-17 11238629-4 2001 PD98059 or U0126 treatment substantially inhibited the BCR-induced activation of the extracellular signal-regulated kinase (ERK) forms of mitogen-activated protein kinase in the immature B cell line WEHI-231, in immature splenic B cells, and in mature splenic B cells. U 0126 11-16 mitogen-activated protein kinase 1 Mus musculus 85-122 11238629-4 2001 PD98059 or U0126 treatment substantially inhibited the BCR-induced activation of the extracellular signal-regulated kinase (ERK) forms of mitogen-activated protein kinase in the immature B cell line WEHI-231, in immature splenic B cells, and in mature splenic B cells. U 0126 11-16 mitogen-activated protein kinase 1 Mus musculus 124-127 10679258-5 2000 Topical treatment of ears with the MEK inhibitor, U0126, prevents ERK phosphorylation and ear swelling in a dose-dependent manner in this model. U 0126 50-55 mitogen-activated protein kinase 1 Mus musculus 66-69 10737896-3 2000 Exposure of the cells to two structurally unrelated mitogen-activated protein kinase or ERK kinase (MEK) inhibitors, PD98059 and U0126, completely abrogated ERK activation but did not prevent tyrosine phosphorylation of p125(Fak), p130(Cas), and paxillin. U 0126 129-134 mitogen-activated protein kinase 1 Mus musculus 88-91 10737896-3 2000 Exposure of the cells to two structurally unrelated mitogen-activated protein kinase or ERK kinase (MEK) inhibitors, PD98059 and U0126, completely abrogated ERK activation but did not prevent tyrosine phosphorylation of p125(Fak), p130(Cas), and paxillin. U 0126 129-134 mitogen-activated protein kinase 1 Mus musculus 157-160 10722758-6 2000 ERK was selectively activated in MLE-15 cells by hypertonic stress, and inhibition of ERK activation with two distinct mitogen-activated extracellular regulated kinase kinase (MEK) inhibitors, U0126 and PD98059, blocked AQP5 induction. U 0126 193-198 mitogen-activated protein kinase 1 Mus musculus 0-3 10722758-6 2000 ERK was selectively activated in MLE-15 cells by hypertonic stress, and inhibition of ERK activation with two distinct mitogen-activated extracellular regulated kinase kinase (MEK) inhibitors, U0126 and PD98059, blocked AQP5 induction. U 0126 193-198 mitogen-activated protein kinase 1 Mus musculus 86-89 10876086-0 2000 Neuroprotection by MAPK/ERK kinase inhibition with U0126 against oxidative stress in a mouse neuronal cell line and rat primary cultured cortical neurons. U 0126 51-56 mitogen-activated protein kinase 1 Mus musculus 24-27 10876086-4 2000 Here, we show that a novel MAPK/ERK kinase (MEK) specific inhibitor U0126 profoundly protected HT22 cells against oxidative stress induced by glutamate, which was accompanied by an inhibition of phosphorylation of ERK1/2. U 0126 68-73 mitogen-activated protein kinase 1 Mus musculus 32-35 10766856-6 2000 Furthermore, we find that U0126, a specific inhibitor of the ERK-activating kinase, MEK-1/2, protects both HT22 cells and immature primary cortical neuron cultures from glutamate toxicity. U 0126 26-31 mitogen-activated protein kinase 1 Mus musculus 61-64 10649432-5 2000 This observation was further confirmed by experiments using inhibitors of the ERK pathway (i.e., PD and U0126), which increased type I collagen mRNA in MC3T3-E1 cells, indicating that the inhibition of ERK pathway upregulates type I collagen gene expression. U 0126 104-109 mitogen-activated protein kinase 1 Mus musculus 78-81 10649432-5 2000 This observation was further confirmed by experiments using inhibitors of the ERK pathway (i.e., PD and U0126), which increased type I collagen mRNA in MC3T3-E1 cells, indicating that the inhibition of ERK pathway upregulates type I collagen gene expression. U 0126 104-109 mitogen-activated protein kinase 1 Mus musculus 202-205 34926455-7 2021 This regulating effect was discounted by TAZ knockdown or the use of MEK-ERK pathway inhibitor, UO126. U 0126 96-101 mitogen-activated protein kinase 1 Mus musculus 73-76 32502508-8 2020 Treatment with alpha7nAChR agonist PNU282987 or ERK inhibitor U0126 reversed Abeta-induced 5-HT1A and 5-HT2C receptor changes. U 0126 62-67 mitogen-activated protein kinase 1 Mus musculus 48-51 34872456-10 2021 Finally, it showed that inhibiting signaling ERK1/2 pathway could aggravate the depressive behavior when treatment with ERK-specific inhibitor U0126, while the condition could be partially relieved when treated with paeoniflorin. U 0126 143-148 mitogen-activated protein kinase 1 Mus musculus 120-123 34244422-5 2021 Furthermore, using an MEK inhibitor (U0126), we found that mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling, which is downstream of EphB/ephrin-B signaling, is activated in M3-deficient crypts. U 0126 37-42 mitogen-activated protein kinase 1 Mus musculus 136-139 34547509-7 2021 ERK and JAK-STAT signaling were blocked using the inhibitors U0126 and Tofacitinib, respectively. U 0126 61-66 mitogen-activated protein kinase 1 Mus musculus 0-3 34278478-8 2021 An ERK inhibitor (U0126) and/or a histone acetylase inhibitor (anacardic acid; AA) attenuated the overexpression of phospho-ERK1/2 and H3K9ac hyperacetylation by inhibiting the expression of PCAF in PE-induced cardiomyocyte hypertrophy. U 0126 18-23 mitogen-activated protein kinase 1 Mus musculus 3-6 34330273-11 2021 Inhibition of the MEK/ERK pathway or of GSK3beta by the U0126 or azakenpaullone compounds respectively significantly restores the impaired differentiation observed in Hrs-depleted cells. U 0126 56-61 mitogen-activated protein kinase 1 Mus musculus 22-25 34421344-3 2021 In the present study, we determined whether targeting MAPK/ERK pathway using MEK inhibitor U0126 could ameliorate DCM by regulating IRE1alpha-XBP1s pathway. U 0126 91-96 mitogen-activated protein kinase 1 Mus musculus 59-62 34502346-8 2021 The ERK inhibitor (U0126) and Prdx1 siRNA affected TLR4/ERK1/2 expression. U 0126 19-24 mitogen-activated protein kinase 1 Mus musculus 4-7 35151202-6 2022 Moreover, apoptosis induced by CdtB was inhibited due to Erk/p38 MAPK signaling pathway suppression performed with SB203580 or U0126. U 0126 127-132 mitogen-activated protein kinase 1 Mus musculus 57-60 35439615-7 2022 More importantly, ERK inhibitor (U0126) or NF-kappaB inhibitor (Bay11-7082) could partially reverse GSK101-induced NLRP3-inflammasome up-regulation. U 0126 33-38 mitogen-activated protein kinase 1 Mus musculus 18-21 35479117-3 2022 This protocol combines icv injection of FGF1 and osmotic mini-pump infusion of U0126, an inhibitor of MAPK/ERK signaling. U 0126 79-84 mitogen-activated protein kinase 1 Mus musculus 102-106 35479117-3 2022 This protocol combines icv injection of FGF1 and osmotic mini-pump infusion of U0126, an inhibitor of MAPK/ERK signaling. U 0126 79-84 mitogen-activated protein kinase 1 Mus musculus 107-110 35479117-4 2022 We describe the surgical procedure and verification of U0126 inhibition of FGF1-stimulated hypothalamic MAPK/ERK signaling via western blot. U 0126 55-60 mitogen-activated protein kinase 1 Mus musculus 104-108 35479117-4 2022 We describe the surgical procedure and verification of U0126 inhibition of FGF1-stimulated hypothalamic MAPK/ERK signaling via western blot. U 0126 55-60 mitogen-activated protein kinase 1 Mus musculus 109-112 35397284-10 2022 U0126 was used to block ERK phosphorylation. U 0126 0-5 mitogen-activated protein kinase 1 Mus musculus 24-27 35490780-6 2022 Accordingly, pharmacological inhibition of the ERK pathway using the upstream kinase inhibitor U0126 ameliorated features of DCM compared to vehicle-treated diabetic mice. U 0126 95-100 mitogen-activated protein kinase 1 Mus musculus 47-50 35490780-7 2022 We demonstrate that ERK inhibition with U0126 also suppressed the phosphorylation of the downstream RSK and YB-1 (S102), which stabilized the interaction between YB-1 and OTUB1 and thereby preserved YB-1 protein expression in diabetic hearts. U 0126 40-45 mitogen-activated protein kinase 1 Mus musculus 20-23 35145518-10 2022 Administration of U0126, a MEK/ERK inhibitor, confirmed this phenomenon, since bigger lesions and higher parasite loads were seen in infected mice that received U0126. U 0126 161-166 mitogen-activated protein kinase 1 Mus musculus 31-34 35355588-12 2022 Mechanistically, Apelin-13 pretreatment inhibited SD/H-induced MSC apoptosis by downregulating mitochondrial fission via activation of the ERK pathway, and these effects were partially abrogated by ERK inhibitor U0126. U 0126 212-217 mitogen-activated protein kinase 1 Mus musculus 139-142 35355588-12 2022 Mechanistically, Apelin-13 pretreatment inhibited SD/H-induced MSC apoptosis by downregulating mitochondrial fission via activation of the ERK pathway, and these effects were partially abrogated by ERK inhibitor U0126. U 0126 212-217 mitogen-activated protein kinase 1 Mus musculus 198-201 35173145-11 2022 U0126, a specific MEK/ERK inhibitor, significantly inhibited either high glucose or rmHPSE-induced EndMT of GEnCs. U 0126 0-5 mitogen-activated protein kinase 1 Mus musculus 22-25 35145518-10 2022 Administration of U0126, a MEK/ERK inhibitor, confirmed this phenomenon, since bigger lesions and higher parasite loads were seen in infected mice that received U0126. U 0126 18-23 mitogen-activated protein kinase 1 Mus musculus 31-34 33744198-9 2021 Overexpression of C/EBPbeta in MEK/ERK pathway inhibited by U0126 did not promote MKs differentiation. U 0126 60-65 mitogen-activated protein kinase 1 Mus musculus 35-38 35003795-6 2022 Hepatic ERK phosphorylation was enhanced in Spred2-/- mice, and pretreatment of Spred2-/- mice with the MAPK/ERK inhibitor U0126 markedly inhibited the liver damage and reduced IFNgamma production. U 0126 123-128 mitogen-activated protein kinase 1 Mus musculus 8-11 35003795-6 2022 Hepatic ERK phosphorylation was enhanced in Spred2-/- mice, and pretreatment of Spred2-/- mice with the MAPK/ERK inhibitor U0126 markedly inhibited the liver damage and reduced IFNgamma production. U 0126 123-128 mitogen-activated protein kinase 1 Mus musculus 109-112 33349854-10 2021 These changes by lower dose combination, except in p-IkappaB expression and NF-kappaB activity, were significantly inhibited by pretreatment with U0126 (ERK inhibitor). U 0126 146-151 mitogen-activated protein kinase 1 Mus musculus 153-156 33788814-6 2021 When DRGs were cultured in the presence of U0126, a pharmacological inhibitor of Erk, the HGF-mediated increase in neurite outgrowth and the level of pSTAT3 (Ser 727) were both suppressed. U 0126 43-48 mitogen-activated protein kinase 1 Mus musculus 81-84 33540617-7 2021 We confirmed the functional relevance for mPFC ERK activation for MA-induced place-preference via site-directed infusion of the MEK inhibitor U0126. U 0126 142-147 mitogen-activated protein kinase 1 Mus musculus 47-50 33681255-10 2021 Additionally, 0.3% formalin-induced up-regulation of phosphorylation of extracellular regulated protein kinases (p-ERK) in the dorsal root ganglion (DRG) and scratching were suppressed by intrathecal injection of MEK inhibitor U0126 in mice. U 0126 227-232 mitogen-activated protein kinase 1 Mus musculus 115-118 33250417-7 2021 Whereas, the addition of inhibitor U0126 down-regulated sharply the expression level of p-ERK, which indicated that cellular osteogenic differentiation of MC3T3-E1 cells was governed through alpha2beta1 integrin-mediated MEK/ERK signaling pathways during CoFe2O4/P(VDF-TrFE) nanocomposite coatings were combined with SMF. U 0126 35-40 mitogen-activated protein kinase 1 Mus musculus 90-93 33250417-7 2021 Whereas, the addition of inhibitor U0126 down-regulated sharply the expression level of p-ERK, which indicated that cellular osteogenic differentiation of MC3T3-E1 cells was governed through alpha2beta1 integrin-mediated MEK/ERK signaling pathways during CoFe2O4/P(VDF-TrFE) nanocomposite coatings were combined with SMF. U 0126 35-40 mitogen-activated protein kinase 1 Mus musculus 225-228 33238752-10 2021 Further experiments revealed that Bach1 knockdown repressed cell viability, alpha-SMA, Fn1, IL-6 and COL1A1 expressions in PF cell model, then ERK inhibition by U0126 enhanced these effects. U 0126 161-166 mitogen-activated protein kinase 1 Mus musculus 143-146 33504418-4 2021 After treated with 1 mug/mL PGRN and ERK1/2 signaling pathway inhibitor U0126 (10 mumol/L) simultaneously, the migration and invasion ability of 4T1 cells and the changes in the expression of E-cadherin, vimentin and p-ERK proteins were detected again. U 0126 72-77 mitogen-activated protein kinase 1 Mus musculus 37-40 33320603-7 2020 However, the addition of the inhibitor U0126 sharply reduced the expression level of p-ERK, which indicated that alpha2beta1 integrin-mediated MEK/ERK signaling pathways play a key role in SMF-assisted cellular osteogenic differentiation over ZnFe2O4 coatings. U 0126 39-44 mitogen-activated protein kinase 1 Mus musculus 87-90 33320603-7 2020 However, the addition of the inhibitor U0126 sharply reduced the expression level of p-ERK, which indicated that alpha2beta1 integrin-mediated MEK/ERK signaling pathways play a key role in SMF-assisted cellular osteogenic differentiation over ZnFe2O4 coatings. U 0126 39-44 mitogen-activated protein kinase 1 Mus musculus 147-150 32822804-7 2020 BD1047, a sigma-1 receptor antagonist, and U0126, an ERK inhibitor significantly induced the Nrf2-related antioxidant potential against behavioral sensitization. U 0126 43-48 mitogen-activated protein kinase 1 Mus musculus 53-56 33097082-10 2020 Inhibition of ERK signaling pathway with U0126 or silencing ERK1/2 effectively blocked the stimulation of osteogenic differentiation induced by HSPB7 knockdown. U 0126 41-46 mitogen-activated protein kinase 1 Mus musculus 14-17 32392918-7 2020 Moreover, NAC and DPI treatment led to a decrease in ERK activity, and the ERK inhibitors PD98059 or U0126 enhanced the mdr1b-Luc activity of H-RasV12-NIH3T3 and reduced doxorubicin-induced apoptosis. U 0126 101-106 mitogen-activated protein kinase 1 Mus musculus 75-78 32782506-6 2020 In addition, the mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor U0126 abrogated the FGF-1- and EGF-mediated suppression of MF marker expression. U 0126 84-89 mitogen-activated protein kinase 1 Mus musculus 57-60 32395078-7 2020 Moreover, NAC and DPI treatment led to a decrease in ERK activity, and the ERK inhibitors PD98059 or U0126 enhanced the mdr1b-Luc activity of H-RasV12-NIH3T3 and reduced doxorubicin-induced apoptosis. U 0126 101-106 mitogen-activated protein kinase 1 Mus musculus 75-78 32450527-9 2020 Inhibition of ERK by inhibitor (U0126) significantly blocked high glucose-induced calcification, which further confirmed the significance of MAPKs. U 0126 32-37 mitogen-activated protein kinase 1 Mus musculus 14-17 32482389-7 2020 Furthermore, the treatment with the ERK inhibitor U0126 and selective Ca2+-permeable AMPA receptor antagonist NASPM completely antagonized the effects of oxytocin. U 0126 50-55 mitogen-activated protein kinase 1 Mus musculus 36-39 32026128-5 2020 U0126, an inhibitor of MAPK/ERK, significantly prevented LIPUS-induced expression of Fos and Egr1, but not that of Jun and Ptgs2. U 0126 0-5 mitogen-activated protein kinase 1 Mus musculus 23-27 32299362-9 2020 In addition, the ERK pathway inhibitor, U0126 (10 muM), significantly reversed the positive effect of TNF-alpha on the protein levels of RUNX2 and BSP. U 0126 40-45 mitogen-activated protein kinase 1 Mus musculus 17-20 32026128-5 2020 U0126, an inhibitor of MAPK/ERK, significantly prevented LIPUS-induced expression of Fos and Egr1, but not that of Jun and Ptgs2. U 0126 0-5 mitogen-activated protein kinase 1 Mus musculus 28-31 32143008-9 2020 While treatment with 5-HT1AR agonist 8-OH-DPAT or ERK inhibitor U0126 exerted no effects or even aggravated Abeta-induced learning and memory decline. U 0126 64-69 mitogen-activated protein kinase 1 Mus musculus 50-53 31968212-7 2020 Inhibitors of the mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) pathway (U0126 and PD0325901) suppressed the uptake of acetylated-LDL (Ac-LDL) and the expression of CD204 but not CD36 in LPS-activated macrophages. U 0126 84-89 mitogen-activated protein kinase 1 Mus musculus 58-61 32046373-10 2020 Denuded oocytes treated with 20 muM U0126 mainly blocked MAPK phosphorylation and affected oocyte maturation. U 0126 36-41 mitogen-activated protein kinase 1 Mus musculus 57-61 32330731-8 2020 Gastrin activates ERK pathway in vivo and in vitro, and treatment with the MEK1 inhibitor U0126 blocked hypergastrinemia-mediated changes, including CCK2R-derived ECL cell hyperplasia in vivo as well as sphere formation and CgA expression in vitro. U 0126 90-95 mitogen-activated protein kinase 1 Mus musculus 18-21 31487015-8 2019 The ERK inhibitor U0126 showed similar inhibition of cell apoptosis, tube formation and HIF-1alpha/VEGF expression as that exhibited by lenti-CGRP. U 0126 18-23 mitogen-activated protein kinase 1 Mus musculus 4-7 31865729-10 2019 Moreover, we found that the overexpression of miR-155 promoted the activation of the ox-LDL-induced NLRP3 inflammasome, which could also be blocked by the ERK inhibitor U0126. U 0126 169-174 mitogen-activated protein kinase 1 Mus musculus 155-158 31878993-12 2019 Compared with PBS group, the phosphorylation of ERK protein on DC was enhanced significantly, and then reduced significantly after U0126 treatment. U 0126 131-136 mitogen-activated protein kinase 1 Mus musculus 48-51 31619255-10 2019 Inhibition of ERK activity (U0126) remarkably enhanced Cav1 and AQP1 expression in bEnd.3 cells. U 0126 28-33 mitogen-activated protein kinase 1 Mus musculus 14-17 31518371-6 2019 Irisin increased extracellular signal-regulated kinase (ERK) phosphorylation, and U0126, an ERK pathway inhibitor, suppressed irisin-induced C2C12 cell proliferation. U 0126 82-87 mitogen-activated protein kinase 1 Mus musculus 92-95 31555361-7 2019 Compared with the SCF single stimulation group, the production of IL-13 was significantly reduced in P815 cells stimulated with U0126 (ERK-MEK/pathway inhibitor) or H-89 (CREB inhibitor) combined with SCF stimulation group (P<0.01). U 0126 128-133 mitogen-activated protein kinase 1 Mus musculus 135-138 31514417-11 2019 The inhibition of ODN-induced N2a differentiation with H89, U73122, chelerythrine and U0126 supports the activation of a PKA/PLC/PKC/MEK/ERK-dependent signaling pathway. U 0126 86-91 mitogen-activated protein kinase 1 Mus musculus 137-140 30938884-10 2019 When we knocked down miR-181a and then treated cells with U0126 before ox-LDL stimulation, we found that U0126 reversed the increased activation of the MEK/ERK/NF-kappaB pathway and upregulation of NLRP3 inflammasome-related proteins (NLRP3, caspase-1, IL-18, IL-1beta) that resulted from miR-181a knockdown. U 0126 58-63 mitogen-activated protein kinase 1 Mus musculus 156-159 30938884-10 2019 When we knocked down miR-181a and then treated cells with U0126 before ox-LDL stimulation, we found that U0126 reversed the increased activation of the MEK/ERK/NF-kappaB pathway and upregulation of NLRP3 inflammasome-related proteins (NLRP3, caspase-1, IL-18, IL-1beta) that resulted from miR-181a knockdown. U 0126 105-110 mitogen-activated protein kinase 1 Mus musculus 156-159 31379571-8 2019 The addition of U0126 and U73122, antagonists of the ERK and PLCgamma pathway, respectively, significantly inhibited cell viability and GAP-43 protein expression. U 0126 16-21 mitogen-activated protein kinase 1 Mus musculus 53-56 31383289-7 2019 Using the Erk pathway inhibitor U0126, we showed that p-Erk was downregulated and the proliferation and migration of K7M2 decreased along with it. U 0126 32-37 mitogen-activated protein kinase 1 Mus musculus 10-13 31383289-7 2019 Using the Erk pathway inhibitor U0126, we showed that p-Erk was downregulated and the proliferation and migration of K7M2 decreased along with it. U 0126 32-37 mitogen-activated protein kinase 1 Mus musculus 56-59 31057410-7 2019 The ERK activation inhibitor U0126 and glucagon-like peptide-1 (GLP-1) receptor antagonist exendin 9-39 abolished the geniposide-induced activation of ERK and inhibited the protective effect of geniposide. U 0126 29-34 mitogen-activated protein kinase 1 Mus musculus 4-7 30920400-8 2019 Moreover, the ERK-specific inhibitor U0126 suppressed the expression of the epithelial-mesenchymal transition of lung cancer cells. U 0126 37-42 mitogen-activated protein kinase 1 Mus musculus 14-17 31844611-18 2019 U0126, an inhibitor of ERK activation, significantly abrogated the protective effects of CoPP. U 0126 0-5 mitogen-activated protein kinase 1 Mus musculus 23-26 31139644-7 2019 ERK inhibitor U0126 reversed the protective effect of chlorogenic acid on colon tissue. U 0126 14-19 mitogen-activated protein kinase 1 Mus musculus 0-3 31057410-7 2019 The ERK activation inhibitor U0126 and glucagon-like peptide-1 (GLP-1) receptor antagonist exendin 9-39 abolished the geniposide-induced activation of ERK and inhibited the protective effect of geniposide. U 0126 29-34 mitogen-activated protein kinase 1 Mus musculus 151-154 29846015-9 2018 In these cells, phospho-p90RSK, phospho-MSK, and Cyclin D1 expression was increased by AKR1B10, and pharmacological inhibition of the ERK signaling cascade with MEK1/2 inhibitors U0126 and PD98059 eradicated induction of phospho-p90RSK, phospho-MSK, and Cyclin D1. U 0126 179-184 mitogen-activated protein kinase 1 Mus musculus 134-137 30072893-10 2018 The effects of the mTOR inhibitor (rapamycin), the PI3K inhibitor (LY294002) and the p-ERK1/2 inhibitor (U0126) suggesting that the ERK/mTOR or PI3K/Akt/mTOR signaling pathway is not involved in the antidepressant effects of CST-14. U 0126 105-110 mitogen-activated protein kinase 1 Mus musculus 87-90 29377587-10 2018 MEK inhibitor U0126 depressed the phosphorylation of ERK-p90RSK and increase in myotube diameter induced by lactate. U 0126 14-19 mitogen-activated protein kinase 1 Mus musculus 53-56 30359975-10 2018 Except for ALP and Col-I, the promotive effects of Nell-1 on the expression of osteogenic markers were suppressed by ERK inhibitor U0126. U 0126 131-136 mitogen-activated protein kinase 1 Mus musculus 117-120 29765986-8 2018 Pretreatment with an inhibitor of p38 (SB203580) or ERK (U0126) attenuated AGE-induced gene expression of proinflammatory cytokines and GM-CSF (real-time PCR), as well as reversing AGE-induced Ki67 expression (IF). U 0126 57-62 mitogen-activated protein kinase 1 Mus musculus 52-55 29207116-12 2018 Additionally, the inductive effect of melatonin on the expression of insulin mRNA was attenuated when the activities of Raf-1 or ERK were blocked using the chemical inhibitors GW5074 and U0126, respectively. U 0126 187-192 mitogen-activated protein kinase 1 Mus musculus 129-132 29199516-4 2018 The protein of arginase-1 was significantly overexpressed in RAW264.7 cells stimulated by TGF-beta1 and high-ambient glucose, which can be partially blocked by not only U0126 (ERK inhibitor) but also SB431542 (Smad2 inhibitor). U 0126 169-174 mitogen-activated protein kinase 1 Mus musculus 176-179 29899190-8 2018 U0126, an inhibitor of ERK activation, completely inhibited the increases in the mRNA levels of DUSP5 and DUSP6. U 0126 0-5 mitogen-activated protein kinase 1 Mus musculus 23-26 29207179-9 2018 We confirmed that an inhibitor of ERK (U0126) or p38 MAPK (SB202190 and SB203580) suppressed the proliferation of the BC3 PEL cells compared with the KSHV-negative DG75 cells. U 0126 39-44 mitogen-activated protein kinase 1 Mus musculus 34-37 29317674-4 2018 Enhanced ERK activation was observed in Spred2-/--livers, and the MEK/ERK inhibitor U0126 ameliorated ALI. U 0126 84-89 mitogen-activated protein kinase 1 Mus musculus 70-73 29299041-9 2017 In addition, the inhibition of ERK1/2 phosphorylation by U0126, a highly selective inhibitor of both MEK1 and MEK2 and a type of MAPK/ERK kinase, up-regulated the expression of collagen VI, while it down-regulated the adipogenic-specific factors. U 0126 57-62 mitogen-activated protein kinase 1 Mus musculus 129-133 28322449-4 2018 And the downregulation of MAPK-ERK signaling using pharmacological inhibitor U0126 and RNA interference rescued osteoblast differentiation suppressed by TGF-beta, which was confirmed by Alkaline phosphatase (ALP) staining and alizarrn red staining, and the enhanced expression of osteogenesic markers. U 0126 77-82 mitogen-activated protein kinase 1 Mus musculus 31-34 28322449-6 2018 Moreover, we observed that the expression of SMURF1 was decreased, while that of SMAD1 and RUNX2 increased by MAPK-ERK inhibitor U0126 in TGF-beta-treated differentiating preosteoblasts, suggesting that MAPK-ERK regulated the transcription of osteogenesis-related genes. U 0126 129-134 mitogen-activated protein kinase 1 Mus musculus 115-118 28322449-6 2018 Moreover, we observed that the expression of SMURF1 was decreased, while that of SMAD1 and RUNX2 increased by MAPK-ERK inhibitor U0126 in TGF-beta-treated differentiating preosteoblasts, suggesting that MAPK-ERK regulated the transcription of osteogenesis-related genes. U 0126 129-134 mitogen-activated protein kinase 1 Mus musculus 208-211 29299041-9 2017 In addition, the inhibition of ERK1/2 phosphorylation by U0126, a highly selective inhibitor of both MEK1 and MEK2 and a type of MAPK/ERK kinase, up-regulated the expression of collagen VI, while it down-regulated the adipogenic-specific factors. U 0126 57-62 mitogen-activated protein kinase 1 Mus musculus 31-34 29070458-9 2017 Treatment with the ERK inhibitor U0126 also lowered TDI?HSA?induced up?regulation of MUC5AC mRNA in the cells (P<0.05). U 0126 33-38 mitogen-activated protein kinase 1 Mus musculus 19-22 28944838-12 2017 Additionally, the ERK pathway inhibitor U0126 and Wnt pathway inhibitor dickkopf-related protein 1 markedly suppressed the expression of the above genes (P<0.01). U 0126 40-45 mitogen-activated protein kinase 1 Mus musculus 18-21 29204135-4 2017 Extensor digitorum longus (EDL) and soleus muscles from male C57BL/6 mice were isolated, divided into halves, and then incubated with ucOC with or without the pretreatment of ERK inhibitor U0126. U 0126 189-194 mitogen-activated protein kinase 1 Mus musculus 175-178 28925474-10 2017 ERK signaling pathway inhibitor, U0126, was used to pre-treat mice. U 0126 33-38 mitogen-activated protein kinase 1 Mus musculus 0-3 27660267-7 2017 Finally, GSK1016790A-enhanced proliferation was markedly blocked by a MAPK/ERK kinase or p38 MAPK antagonist (U0126 or SB203580, respectively). U 0126 110-115 mitogen-activated protein kinase 1 Mus musculus 70-74 28405735-8 2017 The ERK activation inhibitor U0126 or curcumin was applied 30 min before each TNCB challenge. U 0126 29-34 mitogen-activated protein kinase 1 Mus musculus 4-7 28925474-13 2017 U0126 intervention significantly suppressed UCP1 expression, inhibited ERK signaling pathway, enhanced ATP production, and restrained liver cell apoptosis in mice liver injury model. U 0126 0-5 mitogen-activated protein kinase 1 Mus musculus 71-74 28418405-5 2017 Remarkably, inhibition of ERK1 and ERK2 phosphorylation by U0126 in the dHip prior to Pavlovian-conditioning exacerbated impulsive reward seeking. U 0126 59-64 mitogen-activated protein kinase 1 Mus musculus 35-39 28535682-8 2017 Interestingly, the effect of CTRP6 shRNA or CTRP6 recombinant protein was attenuated by U0126 (a special p-Erk inhibitor) or SB203580 (a special p-p38 inhibitor) in adipocytes. U 0126 88-93 mitogen-activated protein kinase 1 Mus musculus 107-110 28620185-7 2017 Administration of ERK inhibitor U0126 impeded the development of rectal prolapse in c-Abl deficient mice. U 0126 32-37 mitogen-activated protein kinase 1 Mus musculus 18-21 28440453-6 2017 SCRG1 also induced the phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) in these cells and, moreover, a mitogen-activated protein kinase (MAPK)/ERK kinase inhibitor U0126 significantly suppressed the effect of SCRG1 on LPS-induced chemokine CCL22 production. U 0126 186-191 mitogen-activated protein kinase 1 Mus musculus 159-163 27639037-5 2017 A co-treatment with the MEK inhibitor U0126 abolished the increase in the expression of Dmp1 and Fgfr1 by elevated Pi, suggesting the involvement of the MEK/ERK pathway in this up-regulation. U 0126 38-43 mitogen-activated protein kinase 1 Mus musculus 157-160 27658230-7 2016 ERK inhibition by U0126 not only induced recovery of myotube formation in old myoblasts but also facilitated muscle regeneration after injury in aged muscle. U 0126 18-23 mitogen-activated protein kinase 1 Mus musculus 0-3 27436370-7 2017 PD153035 (EGFR inhibitor) and U0126 (ERK inhibitor) inhibited AQP3 expression and also the attachment and outgrowth of blastocysts. U 0126 30-35 mitogen-activated protein kinase 1 Mus musculus 37-40 28034754-5 2017 Mechanistically, phosphorylation of MEK1/2 and ERK1/2 in NPCs was enhanced upon LXR agonist treatment, while abrogation of MEK/ERK phosphorylation by the inhibitors PD98059 and U0126 impaired the proliferation of wildtype NPCs in the presence or absence of LXR agonists. U 0126 177-182 mitogen-activated protein kinase 1 Mus musculus 47-50 27748943-5 2016 When ERK activity was inhibited by U0126, the expression of c-Fos also decreased. U 0126 35-40 mitogen-activated protein kinase 1 Mus musculus 5-8 27629357-6 2016 Pretreating the cells with the ERK kinase1/2 (MEK1/2) inhibitor U0126 obviously inhibited the proliferation of C2C12 cells. U 0126 64-69 mitogen-activated protein kinase 1 Mus musculus 31-34 27343376-0 2016 U0126 attenuates ischemia/reperfusion-induced apoptosis and autophagy in myocardium through MEK/ERK/EGR-1 pathway. U 0126 0-5 mitogen-activated protein kinase 1 Mus musculus 96-99 27343376-3 2016 The aim of this study was to determine the protective effect of 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene (U0126), an ERK kinase inhibitor, on myocardial ischemia/reperfusion (I/R) injury and the mechanisms involved. U 0126 64-124 mitogen-activated protein kinase 1 Mus musculus 137-140 27343376-3 2016 The aim of this study was to determine the protective effect of 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene (U0126), an ERK kinase inhibitor, on myocardial ischemia/reperfusion (I/R) injury and the mechanisms involved. U 0126 126-131 mitogen-activated protein kinase 1 Mus musculus 137-140 27343376-9 2016 Furthermore, the relationship between U0126 and MEK/ERK pathway activation in H/R-induced cardiomyocytes was also investigated. U 0126 38-43 mitogen-activated protein kinase 1 Mus musculus 52-55 27343376-10 2016 U0126 ameliorated H/R injury through inhibition of the MEK/ERK pathway and by suppressing in the downstream EGR-1 expression. U 0126 0-5 mitogen-activated protein kinase 1 Mus musculus 59-62 27343376-11 2016 Together, our research suggests that U0126 may protect against H/R injury by preventing H/R-induced myocardium apoptosis and autophagy via the MEK/ERK/EGR-1 pathway, and may be a potential therapeutic approach for attenuating myocardial I/R injury. U 0126 37-42 mitogen-activated protein kinase 1 Mus musculus 147-150 27402431-4 2016 After injury, the mice were injected with U0126 (MAPK/ERK signaling pathway inhibitor) via the femoral vein. U 0126 42-47 mitogen-activated protein kinase 1 Mus musculus 49-53 27402431-4 2016 After injury, the mice were injected with U0126 (MAPK/ERK signaling pathway inhibitor) via the femoral vein. U 0126 42-47 mitogen-activated protein kinase 1 Mus musculus 54-57 27335313-10 2016 In addition, BCAO-induced mechanical allodynia was significantly decreased by intrathecal administration of U0126, an inhibitor of ERK. U 0126 108-113 mitogen-activated protein kinase 1 Mus musculus 131-134 28152057-7 2017 The nobiletin-induced phase delay was blocked by co-treatment with U0126, an ERK inhibitor. U 0126 67-72 mitogen-activated protein kinase 1 Mus musculus 77-80 28810249-9 2017 Furthermore, we observed that CXCL10 inhibition resulted in less activation of ERK phosphorylation, and ERK pathway inhibition by a specific inhibitor, U0126, prevented CXCL10 induced MRMC proliferation and the activation of phosphorylated ERK. U 0126 152-157 mitogen-activated protein kinase 1 Mus musculus 104-107 28810249-9 2017 Furthermore, we observed that CXCL10 inhibition resulted in less activation of ERK phosphorylation, and ERK pathway inhibition by a specific inhibitor, U0126, prevented CXCL10 induced MRMC proliferation and the activation of phosphorylated ERK. U 0126 152-157 mitogen-activated protein kinase 1 Mus musculus 104-107 27669639-7 2016 In addition, dNPA increased phosphorylation of extracellular signal-regulated kinase (ERK) in Neuro 2A cells, which was completely antagonized by pretreatment with U0126. U 0126 164-169 mitogen-activated protein kinase 1 Mus musculus 47-84 27669639-7 2016 In addition, dNPA increased phosphorylation of extracellular signal-regulated kinase (ERK) in Neuro 2A cells, which was completely antagonized by pretreatment with U0126. U 0126 164-169 mitogen-activated protein kinase 1 Mus musculus 86-89 26645822-7 2016 In addition, we found that the protective effects of GS-Rb1 are dose and time dependent and are partially mediated through phosphorylation of ERK1/2 signaling pathway, as evidenced by the abolishment of GS-Rb1-mediated elevation of p-ERK1/2 expression and inhibition of Cx40 expressions when ERK inhibitor U0126 was used. U 0126 306-311 mitogen-activated protein kinase 1 Mus musculus 142-145 27208502-6 2016 ALK5 inhibition with SB431542 or ALK1/2/3/6 with dorsomorphin-1, inhibition of Smad3 activation with SIS3, and inhibition of the MAPK/Erk1/2 with U0126, demonstrates the involvement of these pathways in BMP9-induced ECM synthesis in MEFs. U 0126 146-151 mitogen-activated protein kinase 1 Mus musculus 129-133 27097549-7 2016 Western blot results identified upregulated Erk phosphorylation in the spinal cord-injured neurons, and also showed that U0126 inhibited phosphorylation of Erk, which is a downstream kinase in the Ras/Raf signaling pathway. U 0126 121-126 mitogen-activated protein kinase 1 Mus musculus 44-47 27097549-7 2016 Western blot results identified upregulated Erk phosphorylation in the spinal cord-injured neurons, and also showed that U0126 inhibited phosphorylation of Erk, which is a downstream kinase in the Ras/Raf signaling pathway. U 0126 121-126 mitogen-activated protein kinase 1 Mus musculus 156-159 27034231-8 2016 In vitro inhibition with the ERK protein inhibitor U0126 mitigated ERK protein activation levels with a concomitant reduction in alkaline phosphatase activity. U 0126 51-56 mitogen-activated protein kinase 1 Mus musculus 29-32 27034231-8 2016 In vitro inhibition with the ERK protein inhibitor U0126 mitigated ERK protein activation levels with a concomitant reduction in alkaline phosphatase activity. U 0126 51-56 mitogen-activated protein kinase 1 Mus musculus 67-70 26102008-7 2016 Further, ERK inhibitors such as PD98059 and U0126 blocked phosphorylation of Nrf2 as well as the protective effect of oxyresveratrol in mitochondria. U 0126 44-49 mitogen-activated protein kinase 1 Mus musculus 9-12 27034344-8 2016 This effect was abolished by treating the mice with U0126, a specific ERK pathway inhibitor, showing that, in vivo, the deleterious role of FPR2 also occurs through an ERK-dependent pathway. U 0126 52-57 mitogen-activated protein kinase 1 Mus musculus 70-73 27034344-8 2016 This effect was abolished by treating the mice with U0126, a specific ERK pathway inhibitor, showing that, in vivo, the deleterious role of FPR2 also occurs through an ERK-dependent pathway. U 0126 52-57 mitogen-activated protein kinase 1 Mus musculus 168-171 26897742-8 2016 RESULTS: MEK/ERK inhibitor U0126 dramatically prevented rhabdosphere formation and down-regulated stem cell markers CD133, CXCR4 and Nanog expression, but enhanced ALDH, MAPK phospho-active p38 and differentiative myogenic markers. U 0126 27-32 mitogen-activated protein kinase 1 Mus musculus 13-16 27349568-6 2016 WISP1 enhanced TLR4 mediated ERK signaling and U0126 (an ERK inhibitor) blocked LPS induced beta3 integrin expression and WISP1 enhanced TNF-alpha release. U 0126 47-52 mitogen-activated protein kinase 1 Mus musculus 57-60 26897742-8 2016 RESULTS: MEK/ERK inhibitor U0126 dramatically prevented rhabdosphere formation and down-regulated stem cell markers CD133, CXCR4 and Nanog expression, but enhanced ALDH, MAPK phospho-active p38 and differentiative myogenic markers. U 0126 27-32 mitogen-activated protein kinase 1 Mus musculus 170-174 26881424-9 2016 Pretreatment of bEND3 cells with C-PTIO (a NO scavenger) or U0126 (a specific ERK inhibitor) significantly reduced OGD-induced S-nitrosylation of Cav-1 in cells and blocked the secretion of Cav-1 and MMP2 and 9 into the media as well as the degradation of fibronectin and laminin beta-1 in OGD and tPA-treated cells. U 0126 60-65 mitogen-activated protein kinase 1 Mus musculus 78-81 26862884-7 2016 NaF-induced expression of c-Fos protein was markedly suppressed with U0126, the inhibitor of both activated and non-activated forms of MAPK/ERK kinase 1/2 (MEK1/2) and BIX02189, the MEK5 inhibitor, but partially with SP600125, the JNK inhibitor and SB203580, the p38 inhibitor. U 0126 69-74 mitogen-activated protein kinase 1 Mus musculus 135-139 26902401-12 2016 Treatment with curcumin or U0126, a specific MAPK inhibitor, or suppression of cellular uptake of copper by siRNA knockdown of copper transporter protein 1 (CTR1) blocked copper-induced cell proliferation. U 0126 27-32 mitogen-activated protein kinase 1 Mus musculus 45-49 26772774-13 2016 Pretreating macrophages with an ERK inhibitor, U0126, dose-dependently antagonized WISP"s synergistic effect on Poly(I:C)-induced TNF-alpha release. U 0126 47-52 mitogen-activated protein kinase 1 Mus musculus 32-35 26107116-8 2015 Stereotaxic injection of U0126, a potent inhibitor of the ERK pathway, within the BLA blocked stress-induced behavioral depression. U 0126 25-30 mitogen-activated protein kinase 1 Mus musculus 58-61 26477505-6 2015 U0126, an inhibitor of ERK, reduced VSMC migration. U 0126 0-5 mitogen-activated protein kinase 1 Mus musculus 23-26 26133391-6 2015 The expression of the KLF8 protein was higher in 10/14 (71.43%) fresh cancer tissues compared with adjacent normal tissues, and the blockade of ERK signaling by U0126 decreased the expression of KLF8 in a time- and dose-dependent manner. U 0126 161-166 mitogen-activated protein kinase 1 Mus musculus 144-147 26012717-2 2015 Using NPCs cultured from PKCepsilon or beta-arrestin2 knockout mice and the MAPK/ERK kinase inhibitor U0126, we demonstrate that regulation of NPC differentiation via the miR-181a/Prox1/Notch1 pathway exhibits ligand-dependent selectivity. U 0126 102-107 mitogen-activated protein kinase 1 Mus musculus 76-80 26012717-2 2015 Using NPCs cultured from PKCepsilon or beta-arrestin2 knockout mice and the MAPK/ERK kinase inhibitor U0126, we demonstrate that regulation of NPC differentiation via the miR-181a/Prox1/Notch1 pathway exhibits ligand-dependent selectivity. U 0126 102-107 mitogen-activated protein kinase 1 Mus musculus 81-84 25707920-6 2015 Further studies demonstrated that the administration of OXT alleviated ASD-like symptoms and significantly inhibited phosphorylation of ERK; the inhibitory effect was similar to that of U0126, an ERK signalling inhibitor. U 0126 186-191 mitogen-activated protein kinase 1 Mus musculus 136-139 25745068-9 2015 U0126, a specific ERK inhibitor, also increased DGAT2 expression and cellular lipid accumulation. U 0126 0-5 mitogen-activated protein kinase 1 Mus musculus 18-21 25527444-8 2015 AQP1 might be a potential target, and the ERK antagonist U0126 could be a new drug for the treatment of HSV-1-induced Bell"s palsy in an early stage. U 0126 57-62 mitogen-activated protein kinase 1 Mus musculus 42-45 26217181-4 2015 Ten nanomolar T, E2 or P4 induced nestin(+) cell proliferation within 20 min and enhanced neurosphere growth over 7 days irrespective of sex, which was abolished by Erk inhibition with 20 muM U0126. U 0126 192-197 mitogen-activated protein kinase 1 Mus musculus 165-168 25976656-17 2015 In addition, U0126 treatment decreased levels of phosphorylated ERK; however, it resulted in increased levels of phosphorylated AKT in endometriotic stromal cells compared with vehicle-treated cells (both P < 0.05). U 0126 13-18 mitogen-activated protein kinase 1 Mus musculus 64-67 26037082-6 2015 NMC stimulation resulted in a significant 3- to 4-fold activation of Akt and Erk, whereas pretreatment with Akt (A6730) and Erk (U0126) inhibitors decreased NMC-induced fibroblast proliferation dose-dependently. U 0126 129-134 mitogen-activated protein kinase 1 Mus musculus 124-127 25483228-9 2015 Furthermore, dorsal hippocampal infusion of the ERK inhibitor U0126 blocked the memory-enhancing effects of BSA-P, but not R5020. U 0126 62-67 mitogen-activated protein kinase 1 Mus musculus 48-51 25707920-6 2015 Further studies demonstrated that the administration of OXT alleviated ASD-like symptoms and significantly inhibited phosphorylation of ERK; the inhibitory effect was similar to that of U0126, an ERK signalling inhibitor. U 0126 186-191 mitogen-activated protein kinase 1 Mus musculus 196-199 25203596-8 2015 And the expression of arginase-1 and TGF-beta1 was partially blocked by the pretreated ERK biochemical inhibitor (U0126) instead of the JNK inhibitor (SP600125) and p38MAPK inhibitor (SB203580). U 0126 114-119 mitogen-activated protein kinase 1 Mus musculus 87-90 24777577-4 2015 The MEK/ERK inhibitor U0126 could inhibit ERK1/2 phosphorylation, further inhibiting the proliferation of NSCs in the SGZ and SVZ but had no effect on the phosphorylation of Akt. U 0126 22-27 mitogen-activated protein kinase 1 Mus musculus 8-11 25562427-4 2015 It also induced phosphorylation of CREB (cAMP response element binding protein), but this effect appeared to be mediated indirectly by extracellular signal-regulated kinase (ERK) rather than directly by PKA, given that it was attenuated by the ERK signaling inhibitor U0126. U 0126 268-273 mitogen-activated protein kinase 1 Mus musculus 135-172 25562427-4 2015 It also induced phosphorylation of CREB (cAMP response element binding protein), but this effect appeared to be mediated indirectly by extracellular signal-regulated kinase (ERK) rather than directly by PKA, given that it was attenuated by the ERK signaling inhibitor U0126. U 0126 268-273 mitogen-activated protein kinase 1 Mus musculus 244-247 23995792-5 2014 The Ras-ERK pathway was responsible for the disruption of stress fibers because inhibition of MEK with UO126 or small interfering RNA (siRNA) against K-Ras or ERK1/2 resulted in restoration of stress fibers and focal adhesions. U 0126 103-108 mitogen-activated protein kinase 1 Mus musculus 8-11 24998254-12 2014 In mechanically stretched cardiomyocytes, CGP53353 (a PKCbetaI inhibitor) prevented ERK phosphorylation and autophagic responses, while U0126 (an ERK inhibitor) blocked autophagic responses. U 0126 136-141 mitogen-activated protein kinase 1 Mus musculus 146-149 25489417-4 2014 Paraquat treatment resulted in activation of ERK, and U0126, inhibitors of the MEK/ERK signaling pathway, prevented apoptosis. U 0126 54-59 mitogen-activated protein kinase 1 Mus musculus 83-86 25275324-10 2014 U0126, a selective MEK/ERK inhibitor, reduced the augmented LPS-induced inflammation in Spred-2(-/-) mice. U 0126 0-5 mitogen-activated protein kinase 1 Mus musculus 23-26 24682241-6 2014 The effect of the extracellular signal-regulated kinase (ERK) inhibitor U0126 was studied by adding U0126 (5 microg/microl, 4 microl) into the culture medium during transient ischemia; as a control, we used treatment of cells with 50 microM of resveratrol. U 0126 72-77 mitogen-activated protein kinase 1 Mus musculus 18-55 23677851-11 2014 In particular, NP-induced cell death was significantly suppressed by U0126, a specific inhibitor of ERK. U 0126 69-74 mitogen-activated protein kinase 1 Mus musculus 100-103 24727856-12 2014 The ERK inhibitor U0126 resulted in lower BUN and serum creatinine, suggesting a mechanistic role of ERK in AKI. U 0126 18-23 mitogen-activated protein kinase 1 Mus musculus 4-7 24727856-12 2014 The ERK inhibitor U0126 resulted in lower BUN and serum creatinine, suggesting a mechanistic role of ERK in AKI. U 0126 18-23 mitogen-activated protein kinase 1 Mus musculus 101-104 24974583-11 2014 Treatment of B16F10 cells with U0126, an ERK inhibitor, or SB203580, a p38 inhibitor, suppressed the migration and invasion abilities of B16F10 cells. U 0126 31-36 mitogen-activated protein kinase 1 Mus musculus 41-44 24793006-8 2014 Inhibition of ERK activation by U0126 blocks the effect of MBG on C/EBPalpha expression and on rosiglitazone-induced adipogenesis. U 0126 32-37 mitogen-activated protein kinase 1 Mus musculus 14-17 24682241-6 2014 The effect of the extracellular signal-regulated kinase (ERK) inhibitor U0126 was studied by adding U0126 (5 microg/microl, 4 microl) into the culture medium during transient ischemia; as a control, we used treatment of cells with 50 microM of resveratrol. U 0126 72-77 mitogen-activated protein kinase 1 Mus musculus 57-60 24682241-6 2014 The effect of the extracellular signal-regulated kinase (ERK) inhibitor U0126 was studied by adding U0126 (5 microg/microl, 4 microl) into the culture medium during transient ischemia; as a control, we used treatment of cells with 50 microM of resveratrol. U 0126 100-105 mitogen-activated protein kinase 1 Mus musculus 57-60 24434636-8 2014 By using specific MAPK-Inhibitors (U0126, SB202190, SP600125) we demonstrated that ERK, p38 and JNK differently regulate each pathway of each cytokine. U 0126 35-40 mitogen-activated protein kinase 1 Mus musculus 83-86 24458360-7 2014 Treatment of obese mice with the ERK inhibitor U0126 rescued Baf60c and Deptor expression in skeletal muscle and lowered blood glucose. U 0126 47-52 mitogen-activated protein kinase 1 Mus musculus 33-36 24337667-2 2014 It has previously been shown that blocking activation of extracellular signal-regulated kinase (ERK) with the MEK inhibitor U0126 mitigates brain damage in rodent models of ischemic stroke. U 0126 124-129 mitogen-activated protein kinase 1 Mus musculus 57-94 24337667-2 2014 It has previously been shown that blocking activation of extracellular signal-regulated kinase (ERK) with the MEK inhibitor U0126 mitigates brain damage in rodent models of ischemic stroke. U 0126 124-129 mitogen-activated protein kinase 1 Mus musculus 96-99 24524846-5 2014 Second, in mouse pain models using formalin and complete Freund adjuvant, we found that acupuncture attenuated the nociceptive behavior and the mechanical allodynia; these effects were blocked when ERK cascade was interrupted by the mitogen-activated protein kinase kinase (MEK)/mitogen-activated protein kinase (MAPK) inhibitor U0126 (.8 mug/muL). U 0126 329-334 mitogen-activated protein kinase 1 Mus musculus 198-201 24480726-9 2014 The MAP kinase-ERK inhibitor, U0126 dose-dependently attenuated the nociceptive behavior and spinal ERK activation to i.t. U 0126 30-35 mitogen-activated protein kinase 1 Mus musculus 15-18 24708812-6 2014 Consistently, intrathecal administration of the ERK phosphorylation inhibitor U0126 dramatically reduces the scratching behaviors induced by histamine and DNFB, but not by chloroquine. U 0126 78-83 mitogen-activated protein kinase 1 Mus musculus 48-51 24480726-9 2014 The MAP kinase-ERK inhibitor, U0126 dose-dependently attenuated the nociceptive behavior and spinal ERK activation to i.t. U 0126 30-35 mitogen-activated protein kinase 1 Mus musculus 100-103 24161965-7 2014 When GL-1 and UL-1 cells were treated with PMA and the MAPK/ERK kinase inhibitor U0126, ABCG2 gene expression levels were elevated above those in untreated cells. U 0126 81-86 mitogen-activated protein kinase 1 Mus musculus 55-59 24406428-7 2014 This inhibitory effect of maleylated-BSA on LPS-induced IL-6 production was eliminated by treatment with an extracellular signal-regulated kinase (ERK) inhibitor, U0126, indicating the involvement of ERK pathways. U 0126 163-168 mitogen-activated protein kinase 1 Mus musculus 108-145 24406428-7 2014 This inhibitory effect of maleylated-BSA on LPS-induced IL-6 production was eliminated by treatment with an extracellular signal-regulated kinase (ERK) inhibitor, U0126, indicating the involvement of ERK pathways. U 0126 163-168 mitogen-activated protein kinase 1 Mus musculus 147-150 24406428-7 2014 This inhibitory effect of maleylated-BSA on LPS-induced IL-6 production was eliminated by treatment with an extracellular signal-regulated kinase (ERK) inhibitor, U0126, indicating the involvement of ERK pathways. U 0126 163-168 mitogen-activated protein kinase 1 Mus musculus 200-203 24161965-7 2014 When GL-1 and UL-1 cells were treated with PMA and the MAPK/ERK kinase inhibitor U0126, ABCG2 gene expression levels were elevated above those in untreated cells. U 0126 81-86 mitogen-activated protein kinase 1 Mus musculus 60-63 24150604-7 2014 Inhibition of the p38 MAPK by SB203580 and ERK by U0126 abolished the upregulatory effect of irisin on UCP-1. U 0126 50-55 mitogen-activated protein kinase 1 Mus musculus 43-46 24294901-12 2014 The effect was blocked by the specific p38 MAPK inhibitor SB203580 and ERK inhibitor U0126. U 0126 85-90 mitogen-activated protein kinase 1 Mus musculus 71-74 24989012-7 2014 Finally, the memory ameliorating effects of alpha- or beta-amyrin on the scopolamine-induced cognitive impairments were significantly blocked by ERK inhibitor U0126. U 0126 159-164 mitogen-activated protein kinase 1 Mus musculus 145-148 24304472-8 2014 Treatment with U0126 reversed the effects of NE on c-Fos expression, p38 mitogen-activated protein kinase (MAPK) phosphorylation and TNF-alpha production, but not NF-kappaB activation in LPS-challenged cardiomyocytes. U 0126 15-20 mitogen-activated protein kinase 1 Mus musculus 107-111 23831393-6 2013 Correspondingly, MSK1 inhibition, via H89, or combined p38 and ERK MAPK inhibition, via SB203580 and U0126, diminished maximally stimulated GRE-regulated promoter activity using high concentrations of glucocorticoids. U 0126 101-106 mitogen-activated protein kinase 1 Mus musculus 63-66 24376709-7 2013 PI3K/AKT inhibitor LY294002 and MAPK/ERK kinase (MEK) inhibitor U0126 treatments study clearly indicated that Pls-mediated cell survival was dependent on the activation of these kinases. U 0126 64-69 mitogen-activated protein kinase 1 Mus musculus 32-36 24376709-7 2013 PI3K/AKT inhibitor LY294002 and MAPK/ERK kinase (MEK) inhibitor U0126 treatments study clearly indicated that Pls-mediated cell survival was dependent on the activation of these kinases. U 0126 64-69 mitogen-activated protein kinase 1 Mus musculus 37-40 24075781-12 2013 Phosphorylation of ERK1/2 and subsequent secretion of MMP-9 were inhibited by the ERK inhibitor U0126 and not regulated by overexpressed IKKalpha. U 0126 96-101 mitogen-activated protein kinase 1 Mus musculus 19-22 24145738-5 2014 In vitro experiments demonstrated that the overexpression of ETBR significantly enhanced the proliferation of oligodendroglioma cells and the activation of ERK compared with the controls, which was eliminated by the selective ETBR inhibitor BQ788 and ERK-specific inhibitor U0126, but not selective endothelin A receptor inhibitor BQ123. U 0126 274-279 mitogen-activated protein kinase 1 Mus musculus 156-159 24145738-5 2014 In vitro experiments demonstrated that the overexpression of ETBR significantly enhanced the proliferation of oligodendroglioma cells and the activation of ERK compared with the controls, which was eliminated by the selective ETBR inhibitor BQ788 and ERK-specific inhibitor U0126, but not selective endothelin A receptor inhibitor BQ123. U 0126 274-279 mitogen-activated protein kinase 1 Mus musculus 251-254 23851027-5 2013 Some mice were administered with U0126, a specific upstream inhibitor of ERK, daily during the recovery phase, beginning at 1day after ischemia until sacrifice. U 0126 33-38 mitogen-activated protein kinase 1 Mus musculus 73-76 23975242-10 2013 Furthermore, our data suggested that LDM-induced up-regulation of TP both in vitro and in vivo is associated with ERK activation, because the inhibition of ERK activity by ERK inhibitor U0126 abrogated LDM-induced TP up-regulation. U 0126 186-191 mitogen-activated protein kinase 1 Mus musculus 114-117 23975242-10 2013 Furthermore, our data suggested that LDM-induced up-regulation of TP both in vitro and in vivo is associated with ERK activation, because the inhibition of ERK activity by ERK inhibitor U0126 abrogated LDM-induced TP up-regulation. U 0126 186-191 mitogen-activated protein kinase 1 Mus musculus 156-159 23975242-10 2013 Furthermore, our data suggested that LDM-induced up-regulation of TP both in vitro and in vivo is associated with ERK activation, because the inhibition of ERK activity by ERK inhibitor U0126 abrogated LDM-induced TP up-regulation. U 0126 186-191 mitogen-activated protein kinase 1 Mus musculus 156-159 23852539-7 2013 Inhibition of MEK-ERK signaling was achieved by injection of the mitogen-activated protein kinase (MAPK)/ERK inhibitor U0126. U 0126 119-124 mitogen-activated protein kinase 1 Mus musculus 18-21 23852539-7 2013 Inhibition of MEK-ERK signaling was achieved by injection of the mitogen-activated protein kinase (MAPK)/ERK inhibitor U0126. U 0126 119-124 mitogen-activated protein kinase 1 Mus musculus 99-103 23852539-7 2013 Inhibition of MEK-ERK signaling was achieved by injection of the mitogen-activated protein kinase (MAPK)/ERK inhibitor U0126. U 0126 119-124 mitogen-activated protein kinase 1 Mus musculus 105-108 23764463-7 2013 Furthermore, Icariin-mediated effects on osteoblasts were dramatically attenuated by treatment with specific inhibitors of MAPKs, U0126 (ERK inhibitor) and SP600125 (JNK inhibitor). U 0126 130-135 mitogen-activated protein kinase 1 Mus musculus 137-140 23021350-7 2013 Furthermore, the expression of HO-1 was markedly suppressed by treatment with the p38 inhibitor, SB203580, and mildly suppressed by the MAPK/ERK kinase inhibitor, U0126. U 0126 163-168 mitogen-activated protein kinase 1 Mus musculus 136-140 23307752-3 2013 In this study, our data demonstrated that ERK inhibitors U0126 and PD98059 blocked glutamate-induced necroptosis in HT-22 cells, indicating the critical role of ERK activation in necroptosis. U 0126 57-62 mitogen-activated protein kinase 1 Mus musculus 42-45 23307752-3 2013 In this study, our data demonstrated that ERK inhibitors U0126 and PD98059 blocked glutamate-induced necroptosis in HT-22 cells, indicating the critical role of ERK activation in necroptosis. U 0126 57-62 mitogen-activated protein kinase 1 Mus musculus 161-164 23369528-5 2013 Inhibition of the extracellular signal-regulated kinase (ERK) pathway by U0126 treatment for 24 and 48h in CMT93-II cells markedly decreased claudin-2 from the apical junctional region and increased TER. U 0126 73-78 mitogen-activated protein kinase 1 Mus musculus 18-55 23369528-5 2013 Inhibition of the extracellular signal-regulated kinase (ERK) pathway by U0126 treatment for 24 and 48h in CMT93-II cells markedly decreased claudin-2 from the apical junctional region and increased TER. U 0126 73-78 mitogen-activated protein kinase 1 Mus musculus 57-60 23373714-6 2013 KEY RESULTS: ER stress dampened insulin-stimulated signals and glucose uptake, whereas treatment with the specific ERK inhibitor U0126 (25 muM) rescued impaired insulin signalling via AMPK activation. U 0126 129-134 mitogen-activated protein kinase 1 Mus musculus 115-118 23438680-4 2013 Interestingly, we found that zymosan-induced production of MIP-2 was blocked by pre-treatment with U0126, an inhibitor of mitogen-activated protein kinase/extracellular-signal-regulated kinase (ERK), and with BAY11-7082, an inhibitor of nuclear factor (NF)-kappaB. U 0126 99-104 mitogen-activated protein kinase 1 Mus musculus 194-197 23438680-5 2013 Western blot analysis indicated that U0126 also inhibited the phosphorylation of p65 subunit of NF-kappaB (p65), indicating that MIP-2 was produced via the ERK/NF-kappaB pathway. U 0126 37-42 mitogen-activated protein kinase 1 Mus musculus 156-159 23359590-11 2013 Inhibition of phosphoinositide 3-kinase (PI3K) by Ly294002 or inhibition of ERK by U0126 in vivo abolished CpG-ODN attenuation of CLP-induced cardiac dysfunction. U 0126 83-88 mitogen-activated protein kinase 1 Mus musculus 76-79 23021350-7 2013 Furthermore, the expression of HO-1 was markedly suppressed by treatment with the p38 inhibitor, SB203580, and mildly suppressed by the MAPK/ERK kinase inhibitor, U0126. U 0126 163-168 mitogen-activated protein kinase 1 Mus musculus 141-144 24107539-6 2013 Using the pharmacological inhibitor of ERK activation U0126 we show that E2, through ERK activation, is able to enhance COXIV activity. U 0126 54-59 mitogen-activated protein kinase 1 Mus musculus 39-42 23076500-8 2013 The extracellular signal-regulated kinase (ERK) inhibitor, U0126, blocked Gln-induced MKP-1 phosphorylation and protein induction, as well as Gln suppression of CD. U 0126 59-64 mitogen-activated protein kinase 1 Mus musculus 4-41 23076500-8 2013 The extracellular signal-regulated kinase (ERK) inhibitor, U0126, blocked Gln-induced MKP-1 phosphorylation and protein induction, as well as Gln suppression of CD. U 0126 59-64 mitogen-activated protein kinase 1 Mus musculus 43-46 23197743-7 2013 In osteoblasts from males, ERK inhibitor U0126 (U), not p38 inhibitor (S), prevented the inhibitory effects of PTH on mineralization in early or mature osteoblasts. U 0126 41-46 mitogen-activated protein kinase 1 Mus musculus 27-30 22878015-5 2013 However, pretreatment with the p38 MAP kinase inhibitor SB203580 and ERK inhibitor U0126 attenuated NO-induced cell toxicity, ROS production, and caspase-3 activation. U 0126 83-88 mitogen-activated protein kinase 1 Mus musculus 69-72 24107539-6 2013 Using the pharmacological inhibitor of ERK activation U0126 we show that E2, through ERK activation, is able to enhance COXIV activity. U 0126 54-59 mitogen-activated protein kinase 1 Mus musculus 85-88 23089915-6 2013 In parallel, Fas activation increased phosphorylation of ERK1/2, and FasL-induced lipolysis was blunted in the presence of the ERK-inhibitor U0126 or in ERK1/2-depleted adipocytes. U 0126 141-146 mitogen-activated protein kinase 1 Mus musculus 57-60 22396455-9 2012 Finally, pretreatment of the cells with either U0126 (ERK1/2 inhibitor) or ICI 182 780 (ER antagonist) blocked the upregulation of OBR by E(2) and prevented the E(2)-induced phosphorylation of ERK. U 0126 47-52 mitogen-activated protein kinase 1 Mus musculus 54-57 23247123-11 2013 Finally, we showed incubation of macrophages with E. coli, and the ERK inhibitor U0126 increased CFU numbers and decreased intracellular levels of NO. U 0126 81-86 mitogen-activated protein kinase 1 Mus musculus 67-70 22933112-8 2012 The improved response was prevented by U0126, an Erk inhibitor. U 0126 39-44 mitogen-activated protein kinase 1 Mus musculus 49-52 22561298-6 2012 Furthermore, the VCAM-1 induction was significantly prevented by the phosphatidylinositol 3-kinase (PI3K) inhibitor LY-294002, whereas it was accelerated by the ERK inhibitor, U-0126. U 0126 176-182 mitogen-activated protein kinase 1 Mus musculus 161-164 23013130-4 2012 Thus, the aim of the present study was to investigate the effects of an ERK inhibitor (U0126) on amyloidogenesis and cognitive function in Tg2576 mice. U 0126 87-92 mitogen-activated protein kinase 1 Mus musculus 72-75 21889331-5 2012 ERK, JNK, and p38 MAPKs were activated rapidly by PAF in the lungs, and the PAF-induced metastasis of B16F10 was inhibited in a dose-dependent manner by pretreatment with either U0126 (ERK inhibitor), SP600125 (JNK inhibitor), or SB202190 (p38 inhibitor). U 0126 178-183 mitogen-activated protein kinase 1 Mus musculus 0-3 21889331-5 2012 ERK, JNK, and p38 MAPKs were activated rapidly by PAF in the lungs, and the PAF-induced metastasis of B16F10 was inhibited in a dose-dependent manner by pretreatment with either U0126 (ERK inhibitor), SP600125 (JNK inhibitor), or SB202190 (p38 inhibitor). U 0126 178-183 mitogen-activated protein kinase 1 Mus musculus 185-188 22198573-8 2012 Moreover, the mGluR-LTD impairment displayed by the DeltaRG transgenic mice was rescued with the MEK-ERK inhibitor U0126. U 0126 115-120 mitogen-activated protein kinase 1 Mus musculus 101-104 22169949-8 2012 Furthermore, co-treatment with sub-effective dose of U0126, a mitogen-activated protein kinase inhibitor, blocked the upregulation of ERK phosphorylation and impaired memory retrieval, and bicuculline methiodide (BMI), a GABA(A) receptor antagonist, increased ERK phosphorylation induced by the retention trial and facilitated memory retrieval. U 0126 53-58 mitogen-activated protein kinase 1 Mus musculus 134-137 22169949-8 2012 Furthermore, co-treatment with sub-effective dose of U0126, a mitogen-activated protein kinase inhibitor, blocked the upregulation of ERK phosphorylation and impaired memory retrieval, and bicuculline methiodide (BMI), a GABA(A) receptor antagonist, increased ERK phosphorylation induced by the retention trial and facilitated memory retrieval. U 0126 53-58 mitogen-activated protein kinase 1 Mus musculus 260-263 22226905-6 2012 We further identified the signaling pathway of LOX-1/Ca(2+)/ROS/ERK/c-Fos was involved in oxLDL-mediated microRNA-29b overexpression after treating with the MAPTAM (Ca(2+) chelator), NAC (ROS scavenger), U0126 (ERK inhibitor) and c-Fos (one of the AP-1 proteins) shRNA, respectively. U 0126 204-209 mitogen-activated protein kinase 1 Mus musculus 64-67 22157104-10 2012 Pretreatment with U0126 (ERK inhibitor) significantly suppressed the exacerbating effect of progesterone and the expression of inflammatory mediators. U 0126 18-23 mitogen-activated protein kinase 1 Mus musculus 25-28 21354245-7 2011 Pretreatment of rat primary astrocytes with the MAPK kinase inhibitor U0126 or the JNK inhibitor SP600125 strongly inhibited imipramine-stimulated EGR-1 expression. U 0126 70-75 mitogen-activated protein kinase 1 Mus musculus 48-52 21839191-9 2012 The inhibition of the ERK pathway by U0126 blunted the Sr-induced PPARgamma2 repression while restoring the lipid accumulation. U 0126 37-42 mitogen-activated protein kinase 1 Mus musculus 22-25 21989075-9 2011 A transforming-growth-factor-beta receptor 1 kinase inhibitor or Mitogen-activated-Protein-Kinase/Extracellular-Signal-regulated-Kinase kinase (ERK) inhibitor (U-0126) suppressed the proliferation of mesangial cells induced by advanced-glycation-end-product-cholesterol-aggregated-BSA dose-dependently. U 0126 160-166 mitogen-activated protein kinase 1 Mus musculus 144-147 21601581-10 2011 Both nociceptive behavioral response and spinal ERK activation induced by intraplantar capsaicin were reduced by U0126, an upstream inhibitor of ERK phosphorylation. U 0126 113-118 mitogen-activated protein kinase 1 Mus musculus 48-51 21601581-10 2011 Both nociceptive behavioral response and spinal ERK activation induced by intraplantar capsaicin were reduced by U0126, an upstream inhibitor of ERK phosphorylation. U 0126 113-118 mitogen-activated protein kinase 1 Mus musculus 145-148 23233790-8 2012 ERK and p38 were activated by SKF83959, and pretreatment with their inhibitors U0126 and SB203580, respectively, significantly blunted the SKF83959-induced cytoprotection. U 0126 79-84 mitogen-activated protein kinase 1 Mus musculus 0-3 23029347-12 2012 MHC inhibitor BDM and ERK inhibitor U0126 both abolished above effect of AZA. U 0126 36-41 mitogen-activated protein kinase 1 Mus musculus 22-25 21881005-5 2011 The inhibition of HCO(3)(-) absorption was eliminated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK)/ERK inhibitors U0126 and PD98059. U 0126 153-158 mitogen-activated protein kinase 1 Mus musculus 138-141 21667293-6 2011 CCN2 was expressed in B16(F10) cells, and was reduced by the FAK/src inhibitor PP2 and the MEK/ERK inhibitor U0126 indicating that CCN2 acts downstream of these pathways in B16(F10) murine melanoma cells. U 0126 109-114 mitogen-activated protein kinase 1 Mus musculus 95-98 21385599-6 2011 AA induced the ERK phosphorylation, and this was abolished by the treatment of U0126, a pharmacological inhibitor of MEK, an upstream kinase of ERK. U 0126 79-84 mitogen-activated protein kinase 1 Mus musculus 15-18 21385599-6 2011 AA induced the ERK phosphorylation, and this was abolished by the treatment of U0126, a pharmacological inhibitor of MEK, an upstream kinase of ERK. U 0126 79-84 mitogen-activated protein kinase 1 Mus musculus 144-147 21385599-8 2011 U0126 treatment attenuated AA-induced transactivation of AP-1 and NF-kappaB, suggesting that the MEK/ERK signaling pathway regulates COX-2 expression. U 0126 0-5 mitogen-activated protein kinase 1 Mus musculus 101-104 20724126-8 2011 Furthermore, specific pharmacological inhibitors of ERK kinase (U0126) and p38 MAPK (SB203580) also suppressed the production of IL-12 induced by garlic lectin. U 0126 64-69 mitogen-activated protein kinase 1 Mus musculus 52-55 21250784-6 2011 ERK inhibition by U0126 or Nrf2 suppression by Nrf2 RNAi transfection almost completely abrogated the cytoprotection against menadione-induced apoptosis in (-)Sch B-pre-treated cells. U 0126 18-23 mitogen-activated protein kinase 1 Mus musculus 0-3 21292824-7 2011 Consistent with a role for ERKs in GH-induced expression of these genes, treatment with U0126 to block ERK phosphorylation inhibited their GH-induced expression. U 0126 88-93 mitogen-activated protein kinase 1 Mus musculus 27-31 21292824-7 2011 Consistent with a role for ERKs in GH-induced expression of these genes, treatment with U0126 to block ERK phosphorylation inhibited their GH-induced expression. U 0126 88-93 mitogen-activated protein kinase 1 Mus musculus 27-30 21270272-5 2011 Although U0126, an ERK inhibitor, enhanced insulin sensitivity and attenuated oxidative stress-induced insulin resistance, LY294002, an inhibitor of phosphoinositide 3-kinase (PI3K), worsened the insulin resistance. U 0126 9-14 mitogen-activated protein kinase 1 Mus musculus 19-22 21056972-5 2011 When we examined a role for ERK in regulating cardiac MTs, we showed that the MEK/ERK-inhibitor U0126 increased glu-MT density in either control cardiac myocytes or following exposure to hypertrophic agents. U 0126 96-101 mitogen-activated protein kinase 1 Mus musculus 28-31 21056972-5 2011 When we examined a role for ERK in regulating cardiac MTs, we showed that the MEK/ERK-inhibitor U0126 increased glu-MT density in either control cardiac myocytes or following exposure to hypertrophic agents. U 0126 96-101 mitogen-activated protein kinase 1 Mus musculus 82-85 20828639-7 2010 The PI3K and MEK/ERK pathway inhibitors Ly294002 and U0126 reduced RANKL expression levels in vitro. U 0126 53-58 mitogen-activated protein kinase 1 Mus musculus 17-20 22140508-8 2011 Blocking ERK and p38 MAP kinase signaling by U0126 and SB203580, respectively, diminished MSK1 phosphorylation in UVB-irradiated mouse skin. U 0126 45-50 mitogen-activated protein kinase 1 Mus musculus 9-12 21053363-8 2010 We found that the MEK1/2 inhibitor U0126 inhibited OC formation by suppressing the MEK/ERK/c-Fos pathway. U 0126 35-40 mitogen-activated protein kinase 1 Mus musculus 87-90 20816674-7 2010 Furthermore, H2O2 accumulation was also suppressed by U0126, a MEK/ERK inhibitor, in a concentration-dependent manner. U 0126 54-59 mitogen-activated protein kinase 1 Mus musculus 67-70 20738258-3 2010 We found that treatment of HMBA (hexamethylene bisacetamide)-induced MEL cells with the ERK pathway inhibitor UO126 results in an increase in intracellular haem and haemoglobin levels. U 0126 110-115 mitogen-activated protein kinase 1 Mus musculus 88-91 20654633-14 2010 Behavioral experiments showed that U0126, a MAPK/ERK kinase (MEK) inhibitor, dose-dependently attenuated the behavioral response to i.t. U 0126 35-40 mitogen-activated protein kinase 1 Mus musculus 44-48 20654633-14 2010 Behavioral experiments showed that U0126, a MAPK/ERK kinase (MEK) inhibitor, dose-dependently attenuated the behavioral response to i.t. U 0126 35-40 mitogen-activated protein kinase 1 Mus musculus 49-52 20356956-6 2010 Given previous studies demonstrating that the MEK/ERK pathway directly regulates Ets1 activity, we cultured embryonic hearts in the presence of the MEK inhibitor U0126 and found that U0126 induced intra-cardiac cartilage formation, suggesting the involvement of a MEK/ERK/Ets1 pathway in blocking chondrocyte differentiation of cardiac neural crest. U 0126 162-167 mitogen-activated protein kinase 1 Mus musculus 50-53 20942929-7 2010 4- Treatment of CRC cell lines with U0126 markedly reduced serpinE2 mRNA levels, indicating that expression of serpinE2 is likely dependent of ERK activity. U 0126 36-41 mitogen-activated protein kinase 1 Mus musculus 143-146 20595932-4 2010 RESULTS: Screening with inhibitors revealed specific inhibition only with the map kinase (MEK)/extracellular signal regulated kinase (ERK) inhibitor, U0126. U 0126 150-155 mitogen-activated protein kinase 1 Mus musculus 134-137 20361963-5 2010 Induction of cell migration by scratching the confluent monolayer culture of these cells activated both EGFR and ERK, and their inhibitors AG1478 and U0126 substantially suppressed scratch-induced keratinocyte migration. U 0126 150-155 mitogen-activated protein kinase 1 Mus musculus 113-116 20408896-9 2010 In addition, treatment of cont-DCs with U0126, a specific inhibitor of the ERK pathway, reduced the TLR-mediated production by the DCs of IL-23 but not IL-12. U 0126 40-45 mitogen-activated protein kinase 1 Mus musculus 75-78 20557427-6 2010 Stimulation of p90(RSK) in ischemic neurons was downstream of ERK activation because inhibition of MEK1 (MAP kinase/ERK kinase) with its inhibitor U0126 blocked phosphorylation of p90(RSK). U 0126 147-152 mitogen-activated protein kinase 1 Mus musculus 62-65 20483735-6 2010 MAPK activation-loop phosphorylation was elevated in wounds of IL-6Ralpha-deficient mice, and treatment of wounds in these mice with the MEK inhibitor U0126 resulted in a delay in wound healing suggesting that aberrant ERK activation may contribute to improved healing. U 0126 151-156 mitogen-activated protein kinase 1 Mus musculus 219-222 20189822-7 2010 U0126, PD98059 and LY204002 abolished IL-6 induced IL-13 release when they were preincubated with P815 cells, indicating ERK and Akt cell signaling pathways may be involved in the event. U 0126 0-5 mitogen-activated protein kinase 1 Mus musculus 121-124 20356956-6 2010 Given previous studies demonstrating that the MEK/ERK pathway directly regulates Ets1 activity, we cultured embryonic hearts in the presence of the MEK inhibitor U0126 and found that U0126 induced intra-cardiac cartilage formation, suggesting the involvement of a MEK/ERK/Ets1 pathway in blocking chondrocyte differentiation of cardiac neural crest. U 0126 183-188 mitogen-activated protein kinase 1 Mus musculus 50-53 20356956-6 2010 Given previous studies demonstrating that the MEK/ERK pathway directly regulates Ets1 activity, we cultured embryonic hearts in the presence of the MEK inhibitor U0126 and found that U0126 induced intra-cardiac cartilage formation, suggesting the involvement of a MEK/ERK/Ets1 pathway in blocking chondrocyte differentiation of cardiac neural crest. U 0126 183-188 mitogen-activated protein kinase 1 Mus musculus 268-271 20085809-11 2010 The promotion of chondrogenesis by FGF-2 was significantly suppressed by U0126, an inhibitor of the extracellular signal-regulated protein kinase (Erk) pathway, and by Erk-1 siRNA. U 0126 73-78 mitogen-activated protein kinase 1 Mus musculus 100-145 20085809-11 2010 The promotion of chondrogenesis by FGF-2 was significantly suppressed by U0126, an inhibitor of the extracellular signal-regulated protein kinase (Erk) pathway, and by Erk-1 siRNA. U 0126 73-78 mitogen-activated protein kinase 1 Mus musculus 147-150 21220918-10 2010 Importantly, obvious translocation of ERK and RelA/p65 to nuclei was observed in TGF-beta1-treated podocyte, which was reduced by ERK inhibitor U0126. U 0126 144-149 mitogen-activated protein kinase 1 Mus musculus 38-41 19798745-6 2010 Furthermore, inhibitors of the MAPK and PI3K-Akt signaling pathways, U0126 and LY294002, attenuated the effects of PA6CM, significantly increasing the number of apoptotic cells and decreasing the number of viable cells among the ES cell-derived NS/PCs. U 0126 69-74 mitogen-activated protein kinase 1 Mus musculus 31-35 21220918-10 2010 Importantly, obvious translocation of ERK and RelA/p65 to nuclei was observed in TGF-beta1-treated podocyte, which was reduced by ERK inhibitor U0126. U 0126 144-149 mitogen-activated protein kinase 1 Mus musculus 130-133 19651524-7 2009 U0126, PD98059 and LY204002 almost completely abolished GM-CSF induced IL-4 release when they were preincubated with P815 cells for 30 min, indicating ERK and Akt cell signaling pathways may be involved in the event. U 0126 0-5 mitogen-activated protein kinase 1 Mus musculus 151-154 19854889-6 2010 This down-regulation was attenuated by 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126), which blocks the phosphorylation of ERK. U 0126 93-98 mitogen-activated protein kinase 1 Mus musculus 137-140 19770485-7 2009 Pretreatment of BV2 cells with an inhibitor specific for ERK (U0126) markedly abated the expression of ERK and MMP-2. U 0126 62-67 mitogen-activated protein kinase 1 Mus musculus 57-60 19770485-7 2009 Pretreatment of BV2 cells with an inhibitor specific for ERK (U0126) markedly abated the expression of ERK and MMP-2. U 0126 62-67 mitogen-activated protein kinase 1 Mus musculus 103-106 19125248-6 2009 Treatment of tumor cells with U-0126, an inhibitor of mitogen-activated protein kinase/Erk, also down-regulated the expression of MMP11. U 0126 30-36 mitogen-activated protein kinase 1 Mus musculus 87-90 19625374-5 2009 The MEK/ERK inhibitor U0126 eliminated inhibition by bath LPS but had no effect on inhibition by lumen LPS. U 0126 22-27 mitogen-activated protein kinase 1 Mus musculus 8-11 19762761-5 2009 U0126 (an ERK kinase inhibitor) was injected twice, an intraneural injection (20 nmol/2 microL) 30 min before PSL, and a perineural injection (20 nmol/10 microL) on Day 1 after PSL. U 0126 0-5 mitogen-activated protein kinase 1 Mus musculus 10-13 19706403-6 2009 Inhibition of ERK1/2 hyperactivity as a result of Q79R expression was achieved by injection of the MAPK/ERK kinase inhibitor U0126 during pregnancy. U 0126 125-130 mitogen-activated protein kinase 1 Mus musculus 99-103 19706403-6 2009 Inhibition of ERK1/2 hyperactivity as a result of Q79R expression was achieved by injection of the MAPK/ERK kinase inhibitor U0126 during pregnancy. U 0126 125-130 mitogen-activated protein kinase 1 Mus musculus 14-17 19589334-11 2009 injection of M3G evoked a definite activation of ERK in the lumbar dorsal spinal cord, which was prevented dose-dependently by U0126, a MAP kinase-ERK inhibitor. U 0126 127-132 mitogen-activated protein kinase 1 Mus musculus 49-52 19589334-11 2009 injection of M3G evoked a definite activation of ERK in the lumbar dorsal spinal cord, which was prevented dose-dependently by U0126, a MAP kinase-ERK inhibitor. U 0126 127-132 mitogen-activated protein kinase 1 Mus musculus 147-150 19228841-10 2009 Inhibition of phosphorylated ERK (pERK) expression by U0126 reduced endothelial cell death by OGD. U 0126 54-59 mitogen-activated protein kinase 1 Mus musculus 29-32 19447102-5 2009 In addition, we found that treatment of the cells with extracellular signal-regulated kinase (ERK) inhibitor (U0126) reduced lindenenyl acetate-induced HO-1 expression. U 0126 110-115 mitogen-activated protein kinase 1 Mus musculus 55-92 19447102-5 2009 In addition, we found that treatment of the cells with extracellular signal-regulated kinase (ERK) inhibitor (U0126) reduced lindenenyl acetate-induced HO-1 expression. U 0126 110-115 mitogen-activated protein kinase 1 Mus musculus 94-97 18843268-6 2009 Moreover, inhibition of the hippocampal MEK/ERK pathway with the specific MEK inhibitor U0126, decreased depression-like behaviors in the forced swim test and tail suspension test of CRF2-/- mice. U 0126 88-93 mitogen-activated protein kinase 1 Mus musculus 44-47 19428337-3 2009 In the present study we could elucidate the role of extracellular signal-related MAPK in the murine model of LPS-induced acute lung injury by using U0126, a specific inhibitor of MEK1/2, upstream kinases of ERK. U 0126 148-153 mitogen-activated protein kinase 1 Mus musculus 81-85 19428337-3 2009 In the present study we could elucidate the role of extracellular signal-related MAPK in the murine model of LPS-induced acute lung injury by using U0126, a specific inhibitor of MEK1/2, upstream kinases of ERK. U 0126 148-153 mitogen-activated protein kinase 1 Mus musculus 207-210 19428337-4 2009 Phosphorylation of ERK was inhibited by U0126 in vivo as well as in vitro. U 0126 40-45 mitogen-activated protein kinase 1 Mus musculus 19-22 19428337-10 2009 Histological examination of lung tissues revealed that ERK MAPK inhibition using U0126 efficiently attenuated LPS-induced pulmonary inflammatory responses. U 0126 81-86 mitogen-activated protein kinase 1 Mus musculus 55-58 19428337-10 2009 Histological examination of lung tissues revealed that ERK MAPK inhibition using U0126 efficiently attenuated LPS-induced pulmonary inflammatory responses. U 0126 81-86 mitogen-activated protein kinase 1 Mus musculus 59-63 19494320-8 2009 The ERK inhibitor U0126 blocked Gln-induced MKP-1 phosphorylation and protein induction, as well as Gln"s protective activity against endotoxic shock. U 0126 18-23 mitogen-activated protein kinase 1 Mus musculus 4-7 19176641-12 2009 U-0126, the mitogen-activated protein kinase kinase (MAPK kinase) inhibitors blocked ERK activation and cell proliferation induced by diazoxide. U 0126 0-6 mitogen-activated protein kinase 1 Mus musculus 85-88 19493891-6 2009 NaF-induced apoptosis was markedly suppressed by treatment with the JNK inhibitor, SP600125, and mildly suppressed by the MAPK/ERK kinase inhibitor, U0126. U 0126 149-154 mitogen-activated protein kinase 1 Mus musculus 122-126 19493891-6 2009 NaF-induced apoptosis was markedly suppressed by treatment with the JNK inhibitor, SP600125, and mildly suppressed by the MAPK/ERK kinase inhibitor, U0126. U 0126 149-154 mitogen-activated protein kinase 1 Mus musculus 127-130